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Abstract 
Embryo-derived pluripotent stem cells (ePSCs) naturally derive from different 
founder tissues, namely the early and late epiblast, that vary in their cellular 
characteristics. Recent evidence in mice suggests these sources of starting material 
correspond with two states of pluripotency referred to as „naïve‟ and „primed‟, 
respectively. Pluripotency is defined as the ability of a cell to give rise to any 
foetal or subsequent adult cell type. Naïve and primed ePSCs have different 
fundamental properties and only naïve cells can give rise to all cell types of an 
animal, including functional gametes (Nichols & Smith 2009). Until recently, 
naïve ePSCs (also known as embryonic stem cell or ESCs) were only available in 
mouse. After almost 30 years, the first non-mouse ESCs were derived in rat using 
a combination of specific inhibitors that block the FGF-ERK differentiation 
pathway and simultaneously maintain self-renewal through inhibition of GSK3 
(Buehr et al. 2008; Ying et al. 2008). The three inhibitor combination, or 3i, 
included inhibitors of the FGF receptor (PD173074), downstream ERK activity 
(PD0325901) and the GSK3 pathway (CHIR99021). The dual inhibition of 
PD0325901 and CHIR99021, termed 2i, was found to be effective for ESC 
culture; therefore the requirement for PD173074 became dispensable. If 
pluripotent mechanisms are conserved between species, we hypothesise that these 
inhibitors would aid the derivation of naïve ESCs in livestock species i.e. cattle. 
The aim of this study was to assess the effects of these inhibitors on the 
developing bovine embryo. We hypothesised that the use of the inhibitors in 
culture medium would enhance the pluripotent characteristics of blastocysts for 
subsequent ESC culture. To test this idea we cultured in vitro fertilised bovine 
embryos in the presence of the inhibitors to initially assess the effect on embryo 
development. To assess embryo quality, blastocysts were analysed to evaluate the 
total number of cell nuclei. Additionally, mRNA and protein analyses were 
undertaken to characterise the expression of core pluripotent genes and assess if 
the inhibitors had an effect on their expression. 
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We found that culturing bovine embryos in either 3i or 2i did not influence the 
total number of embryos that progressed to the blastocyst stage. A significant 
decrease was observed in the proportion of early vs. late stage blastocysts in 2i, 
which suggested acceleration in the rate of development. In 2i medium, the 
number of cell nuclei in D7 blastocysts was significantly increased in both the 
inner cell mass (ICM) and the outer trophectoderm (TE). Additionally, embryos 
cultured in 2i showed a >2-fold increase in NANOG, a transcription factor at the 
core of the pluripotency network. The ICM-specific pluripotency marker SOX2 
was also up-regulated in the presence of 2i. Both these genes were found to be 
significantly enriched in the ICM of bovine blastocysts. Overall, we conclude that 
bovine blastocysts differ from mouse in their response to 2i signal inhibition and 
molecular control of pluripotency.  
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Introduction 
Embryo-derived Pluripotent Stem Cells (ePSCs) are the unicellular equivalent to a 
whole animal derived from either pre-(embryonic stem cells or ESCs) or post-
(epiblast stem cells or EpiSCs) implantation embryos (Nichols & Smith 2009). 
These cells are capable of indefinite self renewal and have the ability to generate 
all adult cell types (Keefer et al. 2007; Nichols & Smith 2009; Blair et al. 2011). 
First isolated in mice in 1981 (Evans & Kaufman 1981; Martin 1981), these cells 
launched the stem cell revolution that was awarded a Nobel Prize in 2007. Until 
very recently, authentic ESCs could only be derived from a few inbred mouse 
strains (Nagy & Vintersten 2006; Ying et al. 2008). Unsuccessful derivation in all 
other mammals had been attributed to interspecies differences in early embryonic 
development and a lack of understanding in the mechanisms that drive the 
pluripotent cell state (Munoz et al. 2008b; Talbot & Blomberg 2008). 
In 2008, Ying et al. used small molecular weight inhibitors in ESC culture 
medium to stabilize the pluripotent state whilst eliminating the requirement for 
previously fundamental culture resources, namely feeder cells and serum. The 
successful combination of inhibitors of different signalling pathways (3i/2i, for 3 
and 2 inhibitors, respectively) allowed for the first derivation of bona fide ESCs 
from rat (Buehr et al. 2008), previously unpermissive mice strains (Ying et al. 
2008) and helped establish human ESCs with greater resemblance to their mouse 
counterparts (Hanna et al. 2010). The indicative reliance on similar cellular 
pathways in these species suggested more widely conserved mechanisms of 
pluripotency and the potential to enhance the stability of pluripotency in other 
mammalian species (Blair et al. 2011). 
It has been documented in mice that embryo culture in 3i/2i at the beginning of 
cleavage allows for ESC derivation at high efficiencies as cells are shielded from 
differentiation-inducing stimuli (Nichols et al. 2009). The aim of this thesis was to 
characterise pluripotency in cattle (bovine) embryos in response to 3i/2i 
supplementation during culture. I endeavoured to explore the possibility that the 
inhibitors mentioned above also promote pluripotency in cattle, a species 
previously considered as non-permissive for ESC derivation.  
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The first chapter of this thesis will discuss, in context, literature surrounding 
embryology and stem cell biology, and provide insight to both the progress and 
problems in the field over the past 30 years. Chapter Two will provide an account 
of the methodology, equipment and experimental design used for this work. 
Subsequent chapters present all findings of experiments using 3i/2i 
supplementation, including morphological and molecular data, as well as in-
progress protein work. Lastly, the thesis will conclude with a comprehensive 
discussion of these results and conclusions obtained during the course of this 
research. 
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Chapter 1: Literature Review 
1.1 Pre-implantation Embryo Development 
Reproduction in any mammal is still very much an unknown science yet it is 
fundamental to our existence and central to breeding technologies in domestic 
livestock; an important source of income and food. The process of development 
from a single cell to a multicellular organism has many crucial events. Following 
a fixed pattern of continuous growth, one event sets the foundation for the next, 
each phase increasing in structural complexity as the organism develops. Any 
aberration can severely alter the succession of events (Arora 2009). Pre-
implantation development refers to the period prior to an embryo‟s implantation 
into the uterus of an animal. During this period, there are a multitude of changes 
in the physical appearance and molecular characteristics of the embryo and this 
phase is considered highly regulative (Yamanaka et al. 2006). 
One of the earliest events in mammalian development is the first lineage 
segregation marked by the formation of the blastocyst. Cells of the developing 
embryo (commonly termed blastomeres) mitotically divide following successful 
fertilisation. The division process is known as cleavage and blastomeres will 
proceed to exponentially produce smaller cells until the embryo compacts through 
increased cell to cell contact. Figure 1 displays the cleavage stage embryos as they 
lead up to the formation of the blastocyst. The blastocyst is characterised by the 
formation of the blastocoel; a fluid-filled cavity surrounded by the two 
anatomically distinctive lineages; trophectoderm (TE) and inner cell mass (ICM). 
Once the blastocyst has formed, it will progress to expand in size causing the zona 
pellucida (the membrane encasing the embryo) to rupture and disappear (Arora 
2009). Following blastulation, the ICM further differentiates into the hypoblast on 
the blastocoelic surface, whilst the remaining internal cells form the epiblast and 
what will become the embryo proper. As development proceeds the 
trophectoderm and hypoblast contribute exclusively to extra-embryonic tissues 
such as the placenta and primitive endoderm, respectively. Concurrently, the 
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epiblast will give rise to the three primary germ layers of the developing foetus; 
ectoderm, mesoderm, and endoderm (Johnson 2007; Kuijk et al. 2008).  
 
 
Figure 1. Stages of pre-implantation bovine development. Cleavage stage embryos are 
displayed along the top and subsequent divisions will lead to morula compaction (bottom 
left). Two distinct lineages are formed at the blastocyst stage: Inner Cell Mass (ICM) and 
trophectoderm (TE). The ICM then differentiates into Epiblast and Hypoblast in the late 
stage blastocyst. Modified from Yamanaka et al. 2006. 
 
Before lineage specification, blastomeres up to the 8-cell stage in mice are 
considered totipotent, referring to the differentiation potential of these cells. 
Totipotent cells have the ability to give rise to both extra-embryonic tissues as 
well as a live foetus. On the other hand, pluripotent cells have the sole ability to 
give rise to all cell types of the developing embryo, including the gametes, and 
subsequent adult animal. These cells no longer have the capacity to derive the 
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extra-embryonic lineages (Renard et al. 2007; Nowak- Imialek et al. 2011). The 
nascent epiblast, formed at the late blastocyst stage of development, is where 
pluripotent cells first develop and is therefore functionally (and molecularly) 
distinct from blastomeres and early ICM (Nichols & Smith 2009). 
The rate of development is variable amongst different species and blastulation 
occurs post-fertilization at approximately day seven in cattle (Roach et al. 2006), 
day four in mice (Nagy & Vintersten 2006) and between days five to six in human 
embryos (Arora 2009). In cattle, the blastocyst remains suspended in the uterine 
environment for more than a week before attachment to the uterine wall, observed 
around day 20 post-fertilisation (Wathes & Wooding 1980). This differs from the 
murine (mouse) embryo, which immediately starts to implant after entry into the 
uterus at day 4.5 post-fertilisation (Nagy & Vintersten 2006). As mentioned, the 
early events in lineage segregation take place prior to implantation in mice, 
however in late implanting species, such as cattle, there is little known about the 
precise timing of lineage specification. Berg et al. (2011) demonstrated 
convincingly that regulation of certain genes controlling lineage specification is 
different between cattle and mice (section 1.4). This had previously been implied, 
yet unconfirmed, by discrepancies in gene expression patterns. This finding 
showed that, at least between cattle and mice, lineage commitment is not 
necessarily chronologically equivalent and that not all developmental pathways 
are analogous. It has been speculated that this diversity in rate of development (as 
a result of evolution) may explain other cellular differences observed between 
these species and why extrapolation of experimental findings should be cautiously 
considered (Munoz et al. 2008a). Regardless, the mouse model is still the most 
well documented and efficient system for gaining information on new hypotheses 
and will continue to influence research in other species. However, these findings 
have highlighted the importance of taking species differences into account when 
formulating research conclusions. 
6 
 
1.2 IVP of Bovine Embryos 
Since the early 1970‟s, it had become evident that the large pool of oocytes 
produced in female ovaries had many promising applications for exploitation. 
Only a tiny fraction of oocytes residing in the ovary generate live offspring, the 
rest are lost to atresia and are in essence a wasted resource. Techniques such as in 
vitro production (IVP) of embryos have allowed for the utilisation of these 
reservoirs and have become instrumental for manipulation experiments, and the 
subsequent acquisition of knowledge on the physiological and molecular 
functioning of early development. Nevertheless, extensive research is still 
required to increase efficiencies to those achieved by in vivo counterparts (Galli & 
Lazzari 1996; Hansen 2006).  
IVP consists of three biological steps; in vitro maturation (IVM), in vitro 
fertilisation (IVF) and embryo culture (IVC). IVC is a critical step as the 
developing embryos are susceptible to a number of perturbations, which can 
ultimately affect the developmental competence of the resulting blastocyst and 
subsequent offspring (Wagtendonk-de Leeuw et al. 2000). Following fertilisation, 
the proportion of presumptive zygotes that reach the blastocyst stage in culture 
varies and is dependent largely on the intrinsic qualities of the oocyte. However, 
different laboratory procedures and culture conditions, including media 
supplementation, have a large role in determining embryo quality in vitro. 
Obviously, a key research objective regarding IVP is focused on suitable medium 
formulations that enhance the developmental competency of embryos (Feugang et 
al. 2008).  
Most commonly, a two step culture system is used for embryo culture using 
synthetic oviductal fluid (SOF) medium (Tervit et al. 1972). In vivo, the embryo 
migrates from the oviduct to the uterine lumen, subsequently entering a different 
micro-environment. It is therefore beneficial for embryo development to mimic 
these changes in vitro. The necessity for a larger consumption of amino acids is 
included in the second step of culture as well as the change in glucose for energy 
requirements, as at blastulation energy demands are high compared with cleavage 
stage embryos (Feugang et al. 2008). For these reasons, change in culture medium 
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from an early SOF to late SOF occurs at day five in cattle when the embryo is 
reaching compaction. The embryo spends a further two days in culture following 
this switch in medium.  
A frequent measure of embryo quality is blastocyst rate, measured at day seven 
when embryos are expected to be at least at an early blastocyst stage in 
development (Galli et al. 2003). Lindner & Wright, Jr (1983) found that embryo 
stage alone was not a good predictor of success, whereas embryos classified by 
excellent, good, fair and poor morphology had resulting pregnancy rates of 45%, 
44%, 27% and 20%, respectively. Parameters often used to evaluate embryo 
quality include shape, colour, number and compactness of cells, size of the 
perivitelline space, and number of extruded and degenerated cells. These 
parameters together with an embryo‟s stage of development offer a good indicator 
of expected success in establishing pregnancies (Lindner & Wright. Jr 1983). The 
measure of embryo quality is subjectively based on individual assessment and 
guidelines from different laboratories. However, as a standard measure of embryo 
success in vitro it has proved reliable as it is not always possible to perform the 
definitive test of deriving a live animal.  
In vitro production is an attractive technique for generating abundant low-cost 
embryos for embryo analysis, diagnostics, and basic research processes (Hoshi 
2003). It has become well established in cattle, as pioneering systems in the 
mouse proved useful yet inadequate for bovine embryo needs (Thompson et al. 
2000). Additionally, IVP has become a reliable alternative to conventional 
techniques as working in vivo with bovine embryos is both expensive and 
laborious (Munoz et al. 2008b). There have been an ever increasing number of in 
vitro produced embryos used worldwide to establish pregnancies, representative 
of the potential it has for selective breeding schemes that aim to improve 
productive/ reproductive traits in the next generation (Hansen 2006).  
Additionally, the ability to acquire abundant bovine blastocysts through IVP has 
provided scientific researchers with the fundamental means for obtaining valuable 
information on early development and the enigmatic phenomenon of pluripotent 
stem cells; cells that have the capability of giving rise to an entire animal (Talbot 
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& Blomberg 2008). The use of IVP permits a larger number of time-efficient and 
cost-effective studies to be undertaken to uncover the complexities of these cells. 
1.3 Embryo-derived Stem Cells; Naive vs. Primed 
Pluripotent cells can be immortalised in vitro by isolating epiblast tissue from the 
developing blastocyst. This was first achieved in 1981 in mice (Evans & Kaufman 
1981; Martin 1981) and thus announced the birth of embryonic stem cells (ESCs). 
Aside from being a population of undifferentiated cells, a further key 
characteristic of ESCs is their capability of unlimited self-renewal (Nagy & 
Vintersten 2006; Munoz et al. 2008a; Nowak- Imialek et al. 2011). The idea of 
deriving cell lines that indefinitely exhibited pluripotency was an incentive to 
provide a number of technological platforms (i.e. biomedical, transgenic and 
reproductive) with cells which could be reprogrammed effectively with no past 
cellular history (Keefer et al. 2007; Renard et al. 2007; Talbot & Blomberg 2008). 
The problem is that these cells have only been successfully derived in mice, and 
most recently in rat (Buehr et al. 2008). Human ESCs have been reported since 
1998 (Thompson et al, 1998) however, given that they cannot be functionally 
characterised, there is speculation about whether these represent true ESCs 
(Nichols & Smith 2009). Derivation in ungulates, especially domestic species 
such as cattle, has been attempted but with limited success. This is not unexpected 
as almost every other mammalian species is still non-permissive to true ESC 
derivation. Instead, ESC-like cells have been established in many species. 
Although these cells are to some extent morphologically and molecularly similar 
to bona fide ESCs, they cannot be propagated indefinitely in culture and do not 
exhibit the functional requirements of ESCs (Talbot & Blomberg 2008). The most 
stringent criterion for ESC identification is the production of chimaeric animals. A 
chimaera is a single organism that is made up of cells from different embryonic 
origins (Nagy & Rossant 2001). Injection of true ESCs into a cleavage-stage host 
embryo will ultimately result in full ESC contribution to the tissues, and most 
importantly the germ line of the developing foetus (Nagy & Vintersten 2006). 
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Embryo-derived pluripotent stem cells (ePSCs) encompass a number of cell 
populations derived from different sources that subsequently vary in their cellular 
characteristics. ESCs are derived from pre-implantation embryos. Alternatively, 
cells derived from the late epiblast of post-implantation embryos have been 
accordingly named epiblast stem cells or EpiSCs (Nichols & Smith 2009). These 
EpiSCs express all the core transcriptional pluripotency markers (Nanog, Oct4, 
and Sox2) and differentiate into multi-lineages in vitro, but in contrast to ESCs 
have a „flattened‟ morphology, limited capacity for chimera formation, and a 
change in regulation of a number of specification markers associated with 
differentiation (Nichols & Smith 2009; Blair et al. 2011; Huang et al. 2011). 
Another key finding is that female EpiSCs have undergone X chromosome 
inactivation, an epigenetic modification that further suggests these cells are in a 
fundamentally distinct „state‟ of pluripotency from ESCs. For these reasons, 
EpiSCs represent a „primed‟ state as opposed to the „naive‟ state present in ESCs. 
EpiSCs represent a more differentiated state than ESCs; therefore representing a 
step further on the developmental track which is irreversible without genetic 
manipulation. The previous point provides a strong argument as to why these two 
states are distinctively different and represent a true differentiation event. A 
summary of characteristics for the naive and primed pluripotent states is 
illustrated in Figure 2.  
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Figure 2. Comparative schematic of naive and primed pluripotent stem cells. 
Modified from Nichols & Smith, (2009), and Blair et al., (2011).  
 
Species in which ESC-like cells have been derived, e.g. cattle, show 
characteristics argued to closely resemble EpiSCs. This is perhaps puzzling given 
that effort is made to derive these cells at equivalent stages of development when 
pluripotency is first initiated (Nichols & Smith 2009). As mentioned before, there 
are a number of differences in development to consider as to why very few 
species have had ESCs successfully derived.  
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1.4 Intrinsic Control of Pluripotency: 
Transcription Factors 
Cell fate is ultimately driven by transcription factors that act as a switch to 
effectively turn on and off molecular pathways. However, signalling pathways 
that segregate the lineages remain poorly defined (Lu et al. 2008). In all 
mammals, with lesser extent in mice, there is still a huge amount of research 
required into the cellular pathways, and underlying gene expression, which drive 
lineage development. Conventional lineage markers in mice, especially those 
associated with pluripotency, are unspecific for some species (Keefer et al. 2007; 
Munoz et al. 2008b). This is an obvious hurdle that must be resolved to further 
characterise the states of pluripotency and perhaps aid in derivation of naive ESCs 
in other species. The nomenclature used in the following sections adheres to 
general guidelines (Society for the Study of Reproduction, 2008). 
Genes/transcripts are presented in italics compared to non-italicised protein 
names. Moreover, mouse gene and protein names are in lowercase (except the 
first letter) as opposed to uppercase for all other species mentioned. 
1.4.1 Pluripotent epiblast markers 
In the mouse, analyses of the molecular network that regulates pluripotency have 
identified three core transcription factors; Nanog, Oct4 and Sox2. All these factors 
become exclusively expressed in the epiblast of murine blastocysts as well as 
undifferentiated ESCs, and are found to be co-localised. An enhancer, which 
contains both Oct4 and Sox2 binding motifs, is highly active in undifferentiated 
cells and has been found to regulate a huge number of pluripotent-related genes 
(including Nanog) and Oct4-Sox2 themselves, suggestive of a positive feedback 
loop. Knock-out experiments for each gene have resulted in early embryonic 
fatality due to a failure to maintain pluripotent cells. These experiments have 
provided further confirmation of their importance in early lineage segregation 
(Masui et al. 2007).The following looks at each of these factors individually, as 
well as identifying other factors involved in early gene expression. 
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1.4.1.1 NANOG 
The most fundamental transcription factor associated with pluripotency is Nanog. 
Nanog is a highly divergent homeodomain-containing protein that is exclusively 
expressed in pluripotent cells. Silva et al. (2009) experimentally showed that in 
murine embryos Nanog expression is specific to the epiblast tissue. Additionally, 
ICMs of Nanog-null blastocysts failed to properly establish. ICM cells including 
pluripotent epiblast that could not up-regulate Nanog would degenerate through 
differentiation and apoptosis. Intriguingly, without Nanog the hypoblast also 
failed to establish. This suggests either a role of Nanog in specification of 
hypoblast or that survival of the hypoblast is dependent on paracrine signalling 
from the epiblast (Silva et al. 2009). This implicates Nanog at the heart of 
pluripotent signalling in mouse as the specification factor for epiblast.  
In cattle, NANOG expression has been located to the ICM at the blastocyst stage 
suggesting some functional conservation in relation to findings in the mouse.  
However, it has a mosaic pattern at day seven and little is known of its locality 
after this point (Kuijk et al. 2008). Yang et al. (2011) detected transcripts of 
NANOG in bovine embryos at the morula stage with statistically significant up- 
regulation as the embryo proceeded through to late blastocyst. This is consistent 
with the detection of Nanog at the late morula stage in mouse. Interestingly, in 
porcine (pig) embryos NANOG transcripts have been located from as early as the 
4-cell stage through to the late blastocyst, and even some organs (Wolf et al. 
2011). The NANOG protein, however, was reported as undetectable in porcine 
blastocysts at day eight (Kuijk et al. 2008), but present in the epiblast of day 11-
12 late blastocysts. The expression varies between individual embryos and is 
sometimes co-expressed with markers of the hypoblast (Wolf et al. 2011). 
Consequently, NANOG may not play as supportive a role in initial lineage 
development in pig and demonstrates once more why obtaining information 
regarding species-specific signalling pathways is vitally important.  
1.4.1.2 OCT4 
Oct4 (encoded by the gene POU5F1) has had a long history of association with 
early lineage development and is considered one of the core pluripotent factors. It 
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is a POU domain transcription factor which recognises an 8-bp DNA site, hence 
its name Oct4 (Chambers & Tomlinson 2009). Its expression in murine embryos 
becomes progressively restricted to the pluripotent epiblast after initially 
signifying the ICM at blastulation. Trophectoderm cells lose Oct4 expression, and 
alternatively express the marker Cdx2. In mice, Oct4 and Cdx2 are always 
reciprocally expressed as they inhibit one another‟s expression in the blastocyst 
specifying the two lineages; ICM and TE, respectively. Oct4 is required to 
establish the epiblast compartment as Oct4-null embryos will still develop into 
blastocysts but their ICM lineages are not maintained, and consequently 
differentiate (Nichols et al. 1998; Nichols & Smith 2009). Niwa et al. (2000) used 
transfected ESCs with an inducible Oct4 transgene to modify the quantity of Oct4 
and examine its effect. They found that a critical amount of expression was 
required for self- renewal of mouse ESCs (mESCs). An increase in expression 
resulted in differentiation into primitive endoderm and mesoderm, whilst a 
repression in Oct4 caused differentiation into trophectoderm. Overall, this 
established Oct4 as a key regulator for pluripotency in mouse (Niwa et al. 2000).  
Surprisingly, while Oct4 plays an important role in mouse development, its 
significance in other species, remains ill-defined. In cattle, OCT4 is not restricted 
to the ICM but instead has been reported as ubiquitously expressed throughout 
day seven blastocysts. Up until recently there were a lot of contradictory results 
surrounding expression in later development stages. Berg et al. (2011) showed 
that by day 11, OCT4 mRNA expression in the TE was greatly reduced, reflected 
also by the localisation of OCT4 protein seen restricted to the epiblast tissue at the 
equivalent period. This, however, was not due to repression by CDX2 (as seen in 
the mouse). The finding indicated that OCT4 regulation in cattle is not analogous 
to mice in respect to its role setting up the first lineage specification. However, its 
restricted presence in the epiblast at day 11 suggests it may still be important in 
the pluripotent network.  
Figure 3 outlines key differences in NANOG/Nanog and OCT4/Oct4 mRNA and 
Nanog/NANOG and Nanog/OCT4 protein expression between bovine, human and 
murine blastocysts and ESCs (or ESC-like cells). Note that all ESC cultures 
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express both transcription factors uniformly, whereas the corresponding blastocyst 
stage exhibits differential expression between the three species.  
 
 
Figure 3. Differences of OCT4/Oct4 and NANOG/Nanog mRNA and OCT4 and NANOG 
protein expression between bovine, human and murine blastocysts and embryonic stem 
cells (Munoz et al., 2008a). 
 
1.4.1.3 SOX2 
Sox2 is a member of a superfamily of proteins that all possess a High Mobility 
Group (HMG) box DNA binding domain. It binds the Oct4-Sox2 enhancer 
synergistically with Oct4, and is also considered a key member in the 
transcriptional network of pluripotent ESCs. Sox2-null embryos die soon after 
implantation, as attachment sites lack epiblast and extra-embryonic ectoderm 
components (Keramari et al. 2010). Until recently, the activity of Sox2 in ESCs 
had yet to be experimentally confirmed. The model predicted Sox2 as an essential 
regulator due to its close proximity to the Oct4 binding site on the enhancer 
element, indicating they must bind as a complex to activate transcription. 
However, no direct evidence had been acquired. Masui et al. (2007) showed that 
not only is Sox2 required in ESCs for its enhancer activity, but also as a crucial 
regulator of multiple factors that affect Oct4 expression.   
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Furthermore, Kermari et al. (2010) addressed the question of Sox2 contribution at 
an earlier stage in development. They used small-interfering RNA (siRNA) to 
remove all transcripts during pre-implantation development. Intriguingly, 
depletion of Sox2 transcripts at the 2-cell stage resulted in over 76% of embryos 
halted at the morula stage or earlier with a down-regulation of TE-associated 
markers. Their conclusion surmised that the initial function of Sox2 expression is 
to facilitate the formation of the TE lineage. This is also coincident with evidence 
showing Sox2 is the earliest marker of ICM formation in mouse (Guo et al. 2010). 
The importance of these pluripotent markers therefore goes beyond establishment 
of the ICM and ensuing epiblast, but also as key regulators of a wider range of 
functions in the developing embryo.  
The expression of SOX2 in bovine embryos remains fairly ambiguous. SOX2 
transcripts have been reportedly detected in day seven bovine blastocysts within 
the ICM, but also faintly detectable in TE cells. It becomes gradually restricted to 
epiblast tissue of the later stage embryo between days 12-17 (Degrelle et al. 
2005). Other reports have recognized that SOX2 protein is specifically localised 
in the ICM in day seven blastocysts, (Prasanna Kallingappa, personal 
communication) yet this finding has not been published to my knowledge. 
Consequently, SOX2 is acknowledged as an important transcription factor in 
lineage determination in cattle, but its exact functions and interactions with other 
factors are still elusive. 
1.4.1.4 DPPA3  
Dppa3 (otherwise referred to as stella or Pgc7) is a gene that expression has been 
identified as a key marker of pluripotent cell types in both human and mice 
(Bowles et al. 2003; Payer et al. 2003). Sato et al (2002) first described and 
isolated the novel gene Pgc7, that was expressed specifically in early pre-
implantation embryos, primordial germ cells (PGCs) and oocytes. The authors 
found that Pgc7 was expressed in both TE and ICM of murine blastocysts just 
prior to implantation (D3.5), which disappeared post-implantation until the 
emergence of PGCs. Studies by Saitou et al (2002) also convincingly showed that 
the gene‟s expression was restricted in post-implantation embryos to the PGC 
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population and therefore defined these cells from those that gave rise to somatic 
cells. The fact that this gene was specifically expressed in a number of key 
pluripotent cell types has implicated it as an important regulator in lineage 
specification.  
Furthermore, gene knock-out studies in mice have shown that murine embryos 
deficient in Dppa3 cleave but development is severely compromised past the 2 to 
4-cell stage. Some embryos failed to reach the 8-cell stage, and embryos that 
developed further failed to initiate compaction (Bortvin et al. 2004).  Bortvin et al 
(2004) disagree that Dppa3 is required for germ cell specification as indicated by 
their results using knock-out mice, yet they believe that it is important in the early 
pre-implantation embryos.  
Reports on DPPA3 expression in bovine are scarce. One study documented that 
the mRNA expression of a stella variant progressively decreased in expression 
throughout development from the immature oocyte to the blastocyst stage (Thelie 
et al. 2007). However, specific details on the expression in blastocysts were not 
included. This emphasizes a requirement to further characterise DPPA3 
expression in early development in bovine.  
1.4.2 Extra-embryonic markers  
1.4.2.1 CDX2 
The caudal-type homeodomain protein Cdx2 is well known as a marker of the TE 
lineage in mouse. Cdx2 expression is restricted solely to the TE in mouse 
blastocysts and similarly absent in any ESC culture. The loss of Cdx2 in embryos 
through genetic knock-out causes lethality around the time of implantation due to 
failure in epithelial integrity. Additionally, the repression of Nanog and Oct4 in 
TE does not occur in embryos devoid of Cdx2, thus implicating Cdx2 as an 
important regulator for the TE lineage in mouse (Strumpf et al. 2005).   
Kuijk et al. (2008) documented CDX2 protein expression specific to the TE 
lineage in bovine embryos. Similarly, Berg et al. (2011) found a 2-fold increase in 
CDX2 mRNA located in the TE respective to the ICM. Interestingly, CDX2 
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expression was considerably lower compared with OCT4, whereas mouse 
blastocysts contain equivalent levels.  This posed the question of whether CDX2 
had a role in OCT4 repression as seen in the mouse. Experiments involving CDX2 
knockdown embryos resulted in normal OCT4 expression at the blastocyst stage, 
indicating that in cattle CDX2 does not play a role in OCT4 down-regulation.   
1.4.2.2 GATA4 & GATA6 
Equally important markers of the extra-embryonic lineage hypoblast are two 
members of the GATA family of proteins; Gata4 and Gata6. These DNA binding 
proteins are vertebrate zinc fingers that play a crucial role in not only 
embryogenesis but also cell differentiation in later development. In mouse 
inactivation of either Gata4 or -6 genes result in developmental arrest or early 
embryonic lethality, and 30-40% of Gata4-null embryos fail to even gastrulate 
(Nemer & Nemer 2003). ESCs devoid of Gata4 do not differentiate into primitive 
endoderm suggesting a key role in extra-embryonic regulation. Conversely, over 
expression of both closely related factors is sufficient to transform ESCs into 
primitive endoderm. Gata6 expression in early mouse blastocysts has a mosaic 
distribution pattern within the ICM, which is restricted to the hypoblast layer at 
4.5 days post fertilisation (Chazaud et al. 2006). This indicates that the lineage 
potential of individual cells becomes restricted at an early stage, when spatial 
determination is yet to be established.  
Similarly, GATA6 displayed a mottled expression pattern in the ICM of bovine 
blastocysts. In some blastocysts, GATA6 expression was restricted to a set of cells 
that aligned one side of the ICM in a fashion similar to hypoblast in mouse. This 
finding suggests a conserved role for GATA6 in early lineage development in 
cattle (Kuijk et al. 2008). Published information for the localisation of GATA4 in 
cattle is limited. Although, Yang et al (2011) recently reported the localisation of 
GATA4 in the ICM of D8 bovine blastocysts with an increase in GATA4 
transcripts at the expanded and hatched blastocyst stages. 
Cell fate and maintenance, including pluripotency, can be viewed as a coordinated 
network of positive and negative regulation of gene expression rather than the 
sequential on/off molecular events (Rossant 2004). It is therefore important to 
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continue identifying the many players involved and how they interact to organize 
normal embryonic development. It is also central for the derivation of ESCs, to 
understand differences in the underlying factors involved in specification of 
pluripotent epiblast within species.  
1.5 Extrinsic Control of Pluripotency: Signalling 
Pathways 
1.5.1 In-vitro  
Nagy & Vintersten (2006) insisted that ESCs do not exist in vivo but that they are 
entirely a tissue culture artefact dictated by the environment they grow in. This 
notion has been challenged recently by Nichols & Smith (2009) who believe that 
nascent epiblast tissue in intact embryos is set in a poised “ground state” of 
pluripotency equivalent to ESCs in culture. Simply put: it is the shielding from 
differentiation-inducing stimuli that determines the existence of these cells. That 
is, the ability of pluripotency is already present and not acquired, hence the name 
„ground state‟ (Ying et al. 2008). The validity of the previous hypothesis awaits 
the derivation of true ESCs in other species, but introduces the novel idea behind 
using inhibitors of differentiation to enhance derivation of naïve ESCs.  
Mitogen-activated protein kinase (MAPK) pathways are crucial for the 
transmission and response of cellular cues including those associated with cell 
proliferation, growth and differentiation. The large group of proteins are highly 
conserved throughout eukaryotic systems and incorporates the signalling cascade 
„extracellular signal-regulated kinases‟ or ERKs (Madan et al. 2005) outlined in 
Figure 4. The importance of ERK signalling activated by fibroblast growth factors 
(FGF) is well established in murine early development (Lanner & Rossant 2010). 
Fgf4 is a member of the FGF family of proteins which is expressed by 
undifferentiated ESCs (Kunath et al. 2007). Kunath et al. (2007) looked into the 
relationship between Fgf4 and ERK signalling and its influence on mESCs. They 
showed that interference with Fgf or ERK activity by chemical inhibition or 
genetic manipulation limited the ability of mESCs to differentiate, maintaining 
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their pluripotent state. It was therefore concluded that Fgf is an auto-inductive 
signal for ESCs to exit their self-renewal programme and become responsive to 
differentiation.  
 
 
Figure 4. Pluripotent signalling pathways of Wnt, Lif, Fgf and Bmp. The succession of 
effects within the cascade is shown by either activation (blue arrows) or inhibition (red 
bars). Selective inhibition by PD173074, PD0325901 or CHIR99021 is illustrated. 
 
The experiments outlined in Ying et al. (2008) built on the concept of ERK 
inhibition. The importance of this study was the discovery that the use of specific 
FGF/ERK inhibitors, as well as an inhibitor of general biosynthetic activity, 
allowed for the dispensability of undefined culture conditions. Traditionally, 
mESCs had been maintained in culture by a feeder layer of mitotically inactivated 
fibroblasts and foetal calf serum (Evans & Kaufman 1981; Martin 1981). These 
materials could be the source of a number of key influences for ESC growth. As a 
result, further research was necessary to define the exact components required for 
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ESC survival. It was later found that feeder cells could be substituted with the 
cytokine leukaemia inhibitory factor (LIF). Like many cytokines, LIF activates 
JAK proteins, which further mediate the phosphorylation of Stat3 and results in 
the signalling of cells into a self-renewal programme (Kisseleva et al. 2002; Ying 
et al. 2008). Serum was replaced with bone morphogenetic protein (BMP), which 
activates inhibitor of differentiation (Id) proteins as well as exerts an inhibitory 
effect on MAPK/ERK in the mouse embryo (Figure 4), yet how it does so is 
unknown (Qi et al. 2004). However, Ying et al (2008) found that neither LIF nor 
serum/ BMP blocked the activation of ERK in mESCs. They hypothesised that 
these factors work downstream from the ERK cascade and hence specific 
inhibitors of this particular pathway could, if successful, effectively replace the 
need for undefined additives to culture medium. Supplementation of ESC culture 
medium with these inhibitors resulted in propagation of mESCs at a doubling rate 
comparable with standard culture conditions with 90% of cells remaining 
undifferentiated. These authors showed for the first time that mESCs could be 
efficiently propagated and maintained in conditions free from supplementary 
cells, serum or cytokines, thus provoking the hypothesis of „ground state‟ 
pluripotency (Ying et al. 2008). The potential of these inhibitors for naïve ESC 
derivation in other mammals was reinforced after successful derivation of germ- 
line competent ESCs in rat (Buehr et al. 2008). 
The three inhibitor combination, or 3i, included two inhibitors of the FGF receptor 
and ERK activity (SU5402 and PD184352, later substituted with a more specific 
generation of inhibitor; PD173074 and PD0325901) respectively, and an inhibitor 
of the glycogen synthase kinase-3 (GSK3) pathway (CHIR99021). Figure 4 
indicates where each inhibitor exerts its effect along their corresponding 
signalling pathway. The inclusion of a GSK3 inhibitor was necessary to revive the 
loss of cells to apoptosis and allow for greater survival at high clonal densities 
(Ying et al. 2008). The GSK3 pathway was initially discovered for its role in 
glycogen metabolism. Amongst a diverse array of other functions, recently GSK3 
has been implicated in early development as a signalling pathway involved in 
specification of cell fates (Cohen & Frame 2001) and a key participant in the Wnt 
signal transduction pathway. GSK3 phosphorylates β-catenin leading to its 
degradation and the blocked transmission of Wnt signals to the nucleus (Figure 4). 
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Proper regulation of Wnt signalling has been correlated to normal embryo growth 
and development. The inhibition of GSK3 is therefore also important to mitigate 
the loss of correct regulation of Wnt signalling (Renard et al. 2007; Aparicio et al. 
2010). Inhibition of the GSK3 pathway had previously been described by Sato et 
al. (2004) who used the pharmacological inhibitor bromoindirubin-3′-oxime 
(BIO) in human and mouse ESC cultures. ESC propagation was reportedly 
enhanced and the maintenance of undifferentiated cells that expressed pluripotent 
markers (including Nanog and Oct4) were sustained with BIO addition (Sato et al. 
2004). CHIR99021, on the other hand is a more selective inhibitor of the GSK3 
pathway, but also has some non- neural differentiation- inducing properties. As 
this is undesirable, combination with the dominant effects of the ERK inhibitors 
results in completely undifferentiated colonies that can be efficiently expanded 
(Ying et al. 2008). The dual inhibition of PD0325901 and CHIR99021, termed 2i, 
has been found to be a very effective combination for mESCs, and induced 
pluripotent cells (Silva et al. 2008). It has ultimately made the requirement for the 
FGF receptor inhibitor PD173074 redundant.  
1.5.2 3i/2i in-vivo 
Following the success of 3i/2i in mESCs, Nichols et al (2009) speculated whether 
culturing intact pre-implantation embryos in 3i/2i would elicit similar cellular 
responses as ESC culture in-vitro. To test this notion, they cultured embryos in 
3i/2i to examine the relationship and identity between mESCs and pluripotent 
epiblast of the mouse blastocyst. 3i/2i culture from the 8-cell stage for three days 
did not impede formation to the blastocyst nor did it restrain development of the 
ICM (seen in Figure 5.C; Oct4 expression). The number of cells expressing the 
epiblast marker Nanog increased in 2i culture at the expense of hypoblast tissue, 
indicated by the diminished Gata4 expression. Figure 5 summarises these findings 
both in 3i (A & B) and in 2i (C & D). 
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Figure 5. Effect of FGF/ ERK and GSK3 inhibition on inner cell mass development. 
A) Confocal images of mouse blastocysts grown from the 8- cell stage for 3 days in 
3i, medium supplemented by CHIR99021 alone, or supplemented with PD184352 
and SU5402. Embryos were immunostained using antibodies raised against Nanog 
(green) and Gata4 (blue). B) Bar chart showing cell numbers of epiblast (Nanog 
positive, green) and hypoblast (Gata4 positive, blue) of embryos cultured in 
conditions of A. Bars indicate the mean ± s.d. C) Confocal images of mouse 
blastocysts grown from the 8- cell stage for 2 days in 2i, or medium supplemented 
with PD0325901. Embryos were immunostained using antibodies raised against 
Nanog (green), Oct4 (red) and Gata4 (blue). Nuclei were counterstained with DAPI. 
D) Bar chart showing cell numbers of epiblast (Nanog positive, green) and hypoblast 
(Gata4 positive, blue) of embryos cultured in conditions of C. Bars indicate the mean 
± SD. (Nichols et al. 2009). 
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The identity and pluripotency of the epiblast was confirmed by the production of 
chimeras with full contribution including germ line transmission. It was 
concluded that mESCs and pluripotent epiblast exhibit identical properties, and 
hence represent equivalent ground states of pluripotency (Nichols et al. 2009).  
Conclusions were affirmed in studies by Lu et al. (2008) who also used an 
inhibitor of differentiation (PD98059) in culture medium of intact mouse 
embryos. PD098059 is the less specific equivalent to PD0325901 which also 
blocks ERK signalling. This study found that inhibition of ERK activity caused a 
considerable delay in development, as well as a marked attenuation of Cdx2 
expression. The reduction in Cdx2 was also observed by Nichols et al. (2009). 
Together these two studies proposed that culturing embryos in 3i/2i has 
significant positive effects for deriving pluripotent stem cells. The real test will be 
whether using these inhibitors in other species will uncover similar findings.  
1.6 My Research  
The aim of this study was to assess the effects of inhibitors PD173074, 
PD0325901 and CHIR99021 on the developing bovine embryo. We hypothesised 
that the use of these inhibitors in culture medium would enhance the pluripotent 
characteristics of blastocysts for subsequent ESC derivation. 
Firstly, in vitro fertilised (IVF) bovine embryos were generated and cultured with 
and without the presence of 3i/2i in culture medium. Day-seven embryos 
(blastocysts) were graded on morphological quality and developmental stage 
recorded for later statistical analysis. As a measure of blastocyst quality, total cell 
numbers in the ICM and TE lineages were analysed by differential staining. 
Blastocysts were also analysed for the expression and localisation of core 
pluripotent transcription factors and were assessed for whether 2i had any effect 
on these markers. At present molecular tools specific for bovine embryos are 
scarcely available (e.g. antibodies). Therefore, some trailing of tools was 
performed to ensure validity of results prior to testing. Molecular techniques used 
included real-time qPCR and immunocytochemistry to observe gene and protein 
expression patterns, respectively.  
24 
 
Results obtained will add to the growing knowledge of mechanisms underlying 
pluripotency in cattle. It will also assist future work in reproductive technologies 
for the New Zealand agricultural sector, as manipulation of embryos in farm 
animals, especially dairy and beef cattle, is becoming increasingly important due 
to a rising demand in agricultural products worldwide. Desirable genotypes (e.g. 
speciality milk, disease resistance, fertility, or adaptation to particular 
environments) from genetically screened embryos could be effectively captured 
through multiplying a few embryonic cells into potentially unlimited numbers of 
pluripotent stem cells. These could then be converted into stem cell-derived 
animals capturing unique genetics for breeding, transgenic and biomedical 
applications (Bjorn Oback, personal communication). Being able to access 
numerous high quality oocytes from females and monopolising subsequent 
embryos would increase genetic output by superior individuals. Ultimately, this 
would lead to an increase in the overall performance within a breeding population 
(Feugang et al. 2008; Galli & Lazzari 2008) and subsequently benefit associated 
agricultural sectors.   
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Chapter 2: Materials and Methods 
2.1 In Vitro Production (IVP) of Bovine Blastocysts 
Standard operating procedures were followed for the in vitro production (IVP) of 
bovine embryos in the embryology laboratory at Agresearch Ltd, Ruakura, 
Hamilton. Modifications to the standard procedure were dependent upon 
conditions of the current experiment. An additional section (2.1.7) is included on 
the manipulation of the procedure for the specific work covered in this thesis. 
Note that all plates were made previously in a sterile laminar flow hood 
(Westinghouse Pty Ltd, NSW) and gassed in a 38°C humidified 5% CO2 
incubator for 2 h prior to in vitro maturation (IVM) and in vitro fertilisation (IVF), 
or gassed with 5% CO2, 7% O2, and 88% N2 within a humidified modular 
incubation chamber (QNA International Pty Ltd., Australia) at 38°C for 2 h prior 
to in vitro culture (IVC). For further details on reagents, solutions and media 
composition see Appendix 1. Information from each day of IVP was recorded 
using a production sheet (Appendix 2) and kept in a personal laboratory book for 
future reference. 
2.1.1 Aspiration - Day -1  
Ovaries were collected from local abattoirs and transported to the aspiration 
laboratory, Ruakura, Hamilton in a thermos flask filled with 29.5- 30.5°C, 0.9% 
saline. The time taken between the removal of ovaries and aspiration was no 
longer than 3 h. Cumulus-oocyte complexes (COC‟s) were recovered from cow 
ovaries by aspiration of follicles between 3 to 10 mm using an 18 g needle under 
vacuum (48 mmHg). The needle was penetrated into the follicle and moved 
around slightly to aid the dislodgment of the oocyte within the follicle. The 
aspirated follicular contents were collected in a 15 ml conical tube filled with 2 ml 
of aspiration media.  
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2.1.2 In vitro Maturation - Day -1  
After completion of aspiration, tubes were transported to the main embryology 
laboratory and searched. Searching consisted of transferring the pellet from the 
conical tubes into a 90 mm petri dish containing additional aspiration media. A 35 
mm petri dish containing H199 medium was prepared for collected COCs. All 
collected COC‟s were transferred to a second dish containing H199 and then once 
more into a 35 mm petri dish containing B199 medium. Ten COC‟s were pipetted 
up in 10 μl of B199 and placed into 40 μl drops of IVM  medium located in IVM 
plates. Each 60 mm plate contained 12 drops overlaid with mineral oil, therefore 
holding 120 COC‟s. After all COC‟s were placed into the plates, they were 
returned to the 38°C incubator for a further 22-24 h to allow the oocytes to 
mature.  
2.1.3 In vitro Fertilisation – Day 0  
Freshly thawed additives were dissolved into the sterile IVF medium during plate 
preparation; 10 μl of heparin, 10 μl of pyruvate and 100 μl of penicillamine/ 
hypotaurine per every 10 ml of medium. Each 60 mm plate contained 12 x 30 μl 
drops and 2 x 60 μl wash drops overlaid with mineral oil. Hepes-buffered 
synthetic oviduct fluid (HSOF), used as a transitional/wash medium, required 
warming before use to 38°C.  
In vitro fertilisation occurred in two phases, the first being oocyte preparation. 
Plates containing oocytes from the previous IVM were taken out of the incubator 
and oocytes were removed into a small petri dish with HSOF media. Cumulus 
cells of the COC‟s were loosened by pipetting them up and down several times. 
However, caution was taken not to entirely remove the cumulus cells. A second 
wash was required in another dish of HSOF before a third transfer of the oocytes 
into a small dish of sterile IVF media. Lastly, five oocytes were pipetted up in 10 
μl of the IVF media and transferred into the IVF plate drops.  
Sperm preparation was the second phase of IVF and requires the capacitation of 
frozen semen from 0.25 ml straws. A Percoll Plus gradient was set up in a laminar 
flow hood for sterility. The gradient consisted of 2 ml of 45% Percoll Plus 
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underlaid with 2 ml of 90% Percoll Plus within a 15 ml conical tube. The gradient 
was used to separate the sperm from the semen by centrifugation. The appropriate 
number of straws required for fertilisation, previously determined by experiments 
on the specific bull‟s sperm quality (1-2 straws per run is generally required), was 
thawed from liquid nitrogen storage. Straws removed from liquid nitrogen were 
thawed for 30 s in 30-35°C water. Once removed from the water, the straw tips 
were wiped with ethanol and cut by sterile scissors at the clamped end. The straw 
contents were dispensed into the tube carefully so as to lie gently atop the 45% 
gradient. The tube was then centrifuged for 20 minutes at 2200 rpm (700xg).  
After 20 min, the pellet was aspirated into a sterile glass pipette preloaded with 1 
ml of HSOF. The mixture of sperm and HSOF was placed into a fresh 15 ml 
conical tube and again centrifuged for 5-10 min at 1200 rpm (200xg). This time 
the supernatant was removed by a sterile glass pipette following centrifugation, 
leaving a small pellet of sperm behind. Both centrifugation steps were done as fast 
as possible to ensure that the motile sperm did not start swimming up through the 
supernatant. Next, 200 μl of IVF media was added very gently to the pellet. 
Subsequently, 10 μl was removed and added to 190 μl of sterile H₂O. The 
remaining sperm solution was measured (A) and placed back into an incubator. 
The addition of sperm to the H₂O dilutes it 1:20, but also kills the sperm. A 
further 10 μl is then transferred to a haemocytometer for an accurate sperm count 
under a light microscope. Sperm were counted within the 25 central squares of the 
haemocytometer on both sides to obtain an average cell count (B). The calculation 
is as follows:  
1) Volume measured (A) x Average number of sperm count (B) = Total volume (C) 
   25 
2) Total volume (C) – Volume measured (A) = Volume of IVF to add to tube  
 
The total volume (C) required gives a final concentration of 1 million/ml when the 
sperm is added at a 1:4 dilution (volume of sperm: volume of eggs in 40 μl IVF 
drop). IVF was completed by administering 10 μl of the sperm medium into each 
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drop of five oocytes in the IVF plates. The plates were then returned to the 
incubator for 18-24 h.  
2.1.4 In vitro Culture – Day 1  
On day one post-fertilisation, early synthetic oviduct fluid (ESOF) plates were 
made and placed into an incubation chamber to equilibrate for 2 h. Cumulus cells 
were removed by manual stripping by pipette or by vortexing embryos at 1800 
rpm in hyaluronidase for 2 min. The bare zygotes were then washed through two 
dishes of HSOF. A finely drawn glass pipette (mouth pipette) with a bore size 
slightly larger than the zygote was used to transfer 60 embryos into each IVC 
plate. All embryos were put through a first and second wash drop in each plate, 
then divided up into groups of 10 and transferred into the 6 x 20 μl early synthetic 
oviduct fluid (ESOF) culture drops. Once all zygotes were placed in culture, the 
incubation chamber was gassed with 5% CO2, 7% O2, and 88% N2 for 5 min at 
high pressure. After 5 min, all valves were shut off and the chamber was placed 
into a 38°C incubator for 5 d.  
2.1.5 LSOF change of medium– Day 5  
On day five, late synthetic oviduct fluid (LSOF) plates were made and placed into 
the same incubation chamber to equilibrate for 2 h. During the change over, 
embryos were transferred by mouth pipette to a LSOF plate. Once more, the 
embryos were placed first into the wash drop, then the second wash drop and 
divided into groups of 10 in each of the six culture drops. However, to avoid 
detrimental effects as a consequence of group culture, embryos which had not 
cleaved or looked degenerative at this stage were separated out. The number of 
embryos to cleave was recorded at this stage. Plates were then returned to the 
incubation chambers for re-gassing and a further two days of incubation.  
2.1.6 Grading – Day 7  
Embryos were graded at day seven based on their stage of development and 
morphological quality (grade). The total number, stage of development and grade 
of blastocysts were recorded for personal records as well as for developmental 
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analysis. The criterion for assessment is shown in Appendix 3. Blastocysts were 
processed for either differential staining, RNA extraction or protein analysis as 
outlined in subsequent sections. For a few downstream applications that required 
D8 blastocysts, 5 µl of FCS was added to the 20 µl culture drops following D7 
grading to assist a further overnight incubation.   
2.1.7 3i/2i supplementation  
The basic experimental concept for this thesis relied on supplementation of bovine 
embryo culture media (ESOF & LSOF) with inhibitors of differentiation and 
general biosynthetic activity; PD0325901 and CHIR99021, respectively 
(Stemgent, USA). Collectively, the two inhibitors are referred to as „2i‟. A third 
inhibitor (PD173054, Sigma) was used in initial experiments and in combination 
with the previous inhibitors constitutes „3i‟. Table 1 outlines details of each 
inhibitor, including the working concentrations used in all experiments.  
These concentrations are identical with those used in the mouse system (Nichols 
et al., 2009) and remained consistent throughout these experiments as a 
comparable measure.  
 
Table 1. Inhibitor details for 3i/2i  
  Inhibitor Pathway Stock Dilution Working Solvent 
3i  PD173074 FGFTK 1 mM 1/10000 100 nm DMSO 
2i PD0325901 MEK 10 mM 1/25000 0.4 μM DMSO 
CHIR99021 GSK3 10 mM 1/3333 3 μM DMSO 
 
 
Plates containing culture media supplemented with 3i/2i were made 2 h before 
addition of embryos. Inhibitors were diluted to the correct concentration in ESOF 
or LSOF (whichever applicable) to a total volume of 1 ml. The solvent of all 
inhibitors, di-methylsulphoxide (DMSO), was used as a control and diluted at the 
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equal volume to the combined concentration of inhibitors. Culture plates were 
made according to the standard operating procedure (1 plate of 200 μl = 6 x 20 μl, 
2 x 40 μl drops). Plates were gassed in an incubation chamber with 5% CO2, 7% 
O2, and 88% N2 for 5 min at high pressure and kept in a 38°C incubator until 
required. Any remaining media containing 3i/2i was kept at 4°C and used within 3 
d, otherwise fresh aliquots were made weekly.  
During transfer of embryos into culture, separate glass pipettes were used for each 
treatment to avoid cross contamination of media. Figure 6 outlines the 
experimental design for 3i tests and later refined experiments with 2i. IVF was 
considered as day zero (D0), therefore embryo culture and subsequently the start 
of specific treatments began at day one (D1) post-fertilisation. The treatments of 
3i, 2i or DMSO from D1 were cultured in ESOF + 3i/2i/DMSO for 4 d and LSOF 
+ 3i/2i/DMSO for the last 2 d. Embryos cultured in 3i from day three (D3) were 
cultured in standard ESOF for 2 d, followed by ESOF + 3i for 2 d and then LSOF 
+ 3i for 2 d. Notably, inhibitors were refreshed as a consequence of medium 
change at D5 in the previous treatment groups. The treatment that included the 
addition of 3i at D5 was cultured in standard ESOF up until the D5 changeover, 
followed by culture in LSOF + 3i for the remaining 2 d.   
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Figure 6. Experimental design for embryo culture in 3i/2i. Day (0, 1, 3, 5 and 7) post-
fertilisation is displayed at the top of the figure, as well as corresponding development 
stage and base culture medium for each time period. Treatments for 3i are 1) 3i @ D1, 2) 
3i @ D3, 3) 3i @ D5 and 4) DMSO control. Treatments for 2i are 1) 2i @ D1 and 2) 
DMSO control.  
2.2 Differential Staining 
Working solutions of anti-bovine serum developed in rabbit (RαB, Sigma B3759 
Missouri, USA) and guinea pig compliment serum (GP, Sigma S1639 Missouri, 
USA) were prepared previously. Transfer hepes-buffered synthetic oviduct fluid 
without bovine serum albumin (THSOF -BSA) was added to RαB aliquot at a 1:4 
dilution. A DNA stain (Hoechst 33342, 1 mg/ ml) and propidium iodide (1 
mg/ml) were added at 40 µl /ml, to a GP aliquot diluted 1:4 by THSOF -BSA. 
Plates were prepared with 20 μl drops overlaid with mineral oil. 
Expanded blastocysts were placed in pronase to remove the zona pellucida then 
washed in HSOF before commencing. Embryos were further washed multiple 
times in THSOF –BSA/ + polyvinyl alcohol (PVA, 0.1 mg/ml), a protein-free 
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medium, to prevent transfer of protein into the RαB serum. Embryos were washed 
in RαB drops twice before being left in a third drop for 45 min. 
Subsequently, embryos were washed again in THSOF –BSA/ +PVA thoroughly 
and transferred to a GP plate for 15 min. At this stage it was crucial to have 
embryos out before the specified time otherwise cells lyse and become difficult to 
handle for mounting. After a brief HSOF wash, the embryos were mounted onto 
glass slides using 1.3 μl of Dakocytomation fluorescent mounting medium 
(DAKO, Med-Bio Ltd., S3023, New Zealand) and 9 mm circular cover slips. 
Images were taken immediately using an epi-fluorescence microscope (Olympus 
BX50, Japan).  
Analysis of images was undertaken using Scion Image software (Beta 4.0.2, 
2000). Inner cell mass (ICM) and trophectoderm (TE) cells were counted as 
indicated by blue and pink coloration, respectively. Results were recorded in an 
Excel spreadsheet for further statistical analyses (referred to in section 2.9). 
2.3 Embryo Bisection 
For acquiring separate samples of ICM & TE cells embryos were bisected by 
mechanical means. Expanded blastocysts of high morphological quality (grade 1 
& 2s) were selected for embryo bisection as the ICM was compact and tidy, 
therefore making it easier to visualise and separate during the bisection. 
Blastocysts were placed in 20 µl pronase to remove the zona pellucida and then 
washed twice in phosphate buffered saline (PBS) + MgCl2:6H2O (1.3 mg/L)/ 
CaCl2:6H2O (1 mg/L)/ PVA (0.1 mg/ml). Embryos were transferred in small 
groups (< 5) in 20 µl drops of THSOF -BSA in a 60 mm petri dish. The protein-
free medium caused embryos to settle to the bottom of the dish and become 
„stuck‟. Aid was given to assist embryos to settle in the correct orientation for a 
splitting blade, mounted on a micromanipulator (MO-188, Nikon Narishige, 
Japan), to cut each blastocyst into two portions. One portion contained TE cells 
and the other contained the ICM and overlying TE cells (see Figure 7). Bisected 
pieces of TE and ICM/TE were held on ice in separate dishes containing HSOF 
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for TRIZOL® collection. Bisected embryos were held at this colder temperature 
to slow down any cell degradation that may occur.  
 
 
Figure 7. Bisection procedure for D7/D8 blastocysts. A) Correct orientation of 
embryo in dish, B) „Splitting‟ embryo by mechanical blade C) Bisected pieces of 
ICM/TE and TE cells. 
 
2.4 Immunosurgery 
Working solutions of anti-bovine serum developed in rabbit (RαB, Sigma B3759 
Missouri, USA) and guinea pig compliment serum (GP, Sigma S1639 Missouri, 
USA) were prepared previously. THSOF -BSA was added to the RαB and GP 
aliquots at a 1:4 dilution. Solutions were centrifuged for 10 min, and plates were 
prepared with 20 μl drops overlaid with mineral oil.  
Expanded blastocysts were placed in pronase to remove the zona pellucida then 
washed in HSOF before commencing. Embryos were further washed multiple 
times in THSOF –BSA/ + polyvinyl alcohol (PVA, 0.1 mg/ml), a protein-free 
medium, to prevent transfer of protein into the RαB serum. Embryos were washed 
in RαB drops twice before being left in a third drop for 45 min. Subsequently, 
embryos were stringently washed again in THSOF –BSA/ +PVA and transferred 
through three drops in GP. Embryos were left in the GP plate for a further ~40 
min. Embryos were then removed from the GP and placed into HSOF to dislodge 
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the lysed TE cells. A small bore glass pipette was most effective at removing the 
TE cells from the ICM. The remaining ICM was placed into TRIZOL®. 
2.5 TRIZOL® Collection 
Whole or bisected embryos were added in a droplet of HSOF media on the side of 
an RNase/DNase-free 0.65 ml tube containing 50 µl TRIZOL® (Invitrogen 
#15596-018, Life Technologies, USA). Contents were mixed, by flicking the tube 
lightly, and settled by a brief centrifuge spin. Samples in TRIZOL® were stored at 
-80°C until required for RNA extraction.   
2.6 mRNA Quantification: RT- PCR 
All reagents, unless otherwise stated, were sourced from Invitrogen, Life 
Technologies, USA.  
2.6.1 RNA extraction 
RNA was isolated by firstly adding 1 µl MS2 RNA (200 ng) and 5 µl α globin (5 
pg/µl, Sigma) to each thawed TRIZOL® sample. Chloroform was added at one 
fifth the volume of TRIZOL® (10 µl), mixed, and centrifuged at 4°C for 10 min 
at 7000 rpm. The resulting aqueous phase (~40 µl) was transferred to a fresh tube. 
Isopropanol (40 µl) and 1 µl linear acrylamide (10 µg/µl) were added, followed 
by a 10 min incubation at room temperature. Samples were then centrifuged at 
4°C for 30 min at 13,000 rpm. The supernatant was removed and the pellet 
washed in sterile 70% ethanol (100 µl) for 10 min at 13,000 rpm. The supernatant 
was again removed and the pellet left to air-dry. To finish, the pellet was re-
solubilised in 8 µl DEPC treated H2O. 
2.6.2 DNAse treatment  
RNA samples of 8 µl were treated with 2 µl DNase (1 U/ µl) and 1 µl 10X DNase 
buffer for 60 min at 37°C. The reaction was halted by 65°C incubation with 1 µl 
of EDTA (25 mM) for 10 min. To precipitate out RNA, 1.5 µl sodium acetate and 
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45 µl sterile 100% ethanol were added and the sample left at -80°C for at least 60 
min. Samples were then centrifuged at 13,000 rpm for 30 min to pellet RNA and 
washed with 70% ethanol for a further 10 min spin. Ethanol was aspirated off and 
the RNA pellet re-suspended in 11 µl DEPC-treated H₂O.   
2.6.3 cDNA synthesis 
For first-strand complementary DNA (cDNA), 1 µl random hexamers (50 ng/µl) 
and 1 µl of 10 mM dNTP mix were added to 11 µl total RNA sample and 
incubated for 5 min at 65°C, followed by immediate quenching on ice for 1 min. 
Reverse transcription was performed by the addition of 10 µl master mix 
containing 2 µl 10X buffer, 4 µl of 25 mM MgCl2, 1 µl RNaseOUT (40 U/µl) and 
1 µl Superscript III reverse transcriptase (200 U/µl). The reaction mixture was 
first incubated for 10 min at 25°C, 50 min at 50°C, and then terminated by heating 
to 85°C for 5 min. Immediately, cDNA was quenched on ice for 1 min followed 
by storage at -80°C or PCR. To determine the presence of contaminating genomic 
DNA, reverse transcriptase was omitted in one sample each time a batch of 
samples was processed for cDNA synthesis (“-RT”). 
2.6.4 RT-PCR 
The PCR was performed using a Mastercycler gradient (Eppendorf, Germany) 
with primer sequences shown in Table 2. Primers were originally designed by 
Bjorn Oback in LightCycler® Probe Design 2.0 or NCBI/Primer-BLAST. A total 
of 25 µl of reaction mix was added to 1 µl of cDNA template in a PCR tube. The 
PCR reaction mixture for each RNA sample consisted of 0.5 µl dNTP mix (10 
mM), 0.5 µl of each primer (10 µM), 2.5 µl 10X PCR buffer (incl. MgCl2), 0.2 µl 
Taq polymerase (5 U/µl), and 20.8 µl DEPC-treated H₂O. The following 
conditions were used: 1) denaturation for 5 min at 95°C, 2) amplification cycle of 
94°C for 15 s, 56°C for 30 s followed by 72° for 1 min was repeated 34 times, 3) 
final extended amplification phase of 7 min at 72°C, and 4) cooling to hold at 
4°C.  
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Table 2. RT- PCR and qPCR Primers 
Gene Sequence (5’-3’) RT- PCR 
annealing 
(°C) 
qPCR 
melting 
peak 
(°C) 
Ampli-
con 
size 
(bp) 
18S F:GACTCATTGGCCCTGTAATTGGAATGAGTC 
R: GCTGCTGGCACCAGACTTG 
 
56 84 87 
NANOG F: CACCCATGCCTGAAGAAAGT 
R: TGCATTTGCTGGAGACTGAG 
 
56 87 295 
SOX2 F: CTATGACCAGCTCGCAGA 
R: GGAAGAAGAGGTAACCACG 
 
60 90 152 
OCT4 F: GGTTCTCTTTGGAAAGGTGTTC 
R: TGGCGACGGTTGCAAAACCA 
 
60 90 333 
DPPA3 F: TGCAAGTTGCCACTCAACTC 
R: TCTTACCCCTCTCCGCCCTAT 
 
60 83 158 
CDX2 F: AGACAAATACCGGGTCGTGTACA 
R: TTTGCTCTGCGGTTCTGAA 
 
60 88 162 
  
2.6.5 Gel electrophoresis analysis 
PCR products were loaded into 0.8-1.0% (w/v) agarose gels containing SYBER 
safe
TM
 DNA gel stain (S33102, Invitrogen). Samples were mixed with loading 
dye prior to loading into the gel. Electrophoresed PCR products were run 
simultaneously with a 1 kb+ ladder (10787-018, Invitrogen) for determining their 
molecular sizes.  
2.7 mRNA Quantification: Real-time qPCR 
2.7.1 LightCycler® system  
The LightCycler® system (Roche Diagnostics, USA) was used for qPCR 
amplification and data analysis. All consumables (excluding primers) and 
equipment were sourced from Roche Diagnostics, USA. All reactions were 
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performed with the LightCycler® FastStart DNA Master Plus SYBR Green 1 kit 
within LightCycler® capillaries (20 µl). Primer sequences are shown in Table 2.  
For each sample a reaction mix consisting of 2 µl LightCycler® Master Mix, 0.4 
µl of each primer (10 µM) and 5.2 µl DEPC-H₂O was prepared and added to 2 µl 
of cDNA template in a LightCycler® capillary. Samples were prepared in 
duplicate or triplicate, where possible given very low initial volumes, and 
repeated with at least three different samples of the same treatment. Samples were 
centrifuged (LightCycler® Carousel centrifuge) for 15 s to ensure contents were 
located at the end of each capillary before the reaction commenced. The following 
program was used: 1) denaturation (10 min at 95°C); 2) amplification and 
quantification (20 s at 95°C, 20 s at 56–60°C, followed by 20 s at 72°C with a 
single fluorescent measurement repeated 45 times); 3) melting curve (95°C, then 
cooling to 65 °C for 20 s, heating at 0.2°C s-1 to 95°C while continuously 
measuring fluorescence); and 4) cooling to 4°C.  
Product identity was verified by gel electrophoresis and melting curve analysis. 
Results were analysed using generated standard curves to express concentration 
relative to the concentration of a housekeeping gene (18S). The analysis holds the 
assumption that our treatments had no effect on the concentration of the 
housekeeping gene.    
2.7.2 Melting curve analysis 
Melting curves were analysed in LightCycler® Software (4.1.1.21) after each run. 
A primer pair should have the same melting peak for each sample (except 
negative controls) and be consistent with previous experiments (see Table 2 for 
melting peaks of primers used). If this did not occur it was either due to primer 
dimers or contaminating genomic DNA. Results were discarded if the melting 
peak was not „clean‟ as primers had previously been optimized, and therefore 
could only suggest a problem with the cDNA sample or specific reaction. A non-
template control containing no cDNA was always included in every run and as a 
control should have a different melting peak to the samples. An example melting 
curve analysis is shown in Figure 8 for CDX2 primers.  All samples have a 
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melting peak temperature of 88°C, which is consistent with the optimisation 
results for the particular primer. As expected, the non-template control (no cDNA) 
is different at 79°C. One peak is present at the correct temperature, and therefore 
it can be confirmed that the amplified DNA product in our samples is CDX2.  
 
 
Figure 8. LightCycler® Melting Curve Analysis. Example of melting peaks obtained 
during a real-time qPCR run with CDX2 primers.  
 
2.7.3 Standard curve generation 
RNA was extracted and cDNA produced from a large quantity of blastocysts 
(~60). The subsequent cDNA sample or DNA obtained by gel extraction was used 
to generate standard curves from serial 5-log dilutions. Dilutions for each gene 
were run in duplicate and triplicate at higher dilution ranges dependent on initial 
starting concentrations. The higher the dilutions, the greater number of replicates 
were performed to eliminate bias as the sensitivity of the PCR machine decreased. 
Standard conditions described in section 2.6.1 were used. Curves were generated 
using the LightCycler® Software (4.1.1.21) and information exported to Excel. R 
values and trend line equations were obtained from graphed curves. One high 
efficiency curve (1.90-2.10) was saved for each target gene and the subsequent 
equation used for relative quantification.  
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2.7.4 Gel extraction for standard curves 
Many of the target genes investigated are expressed in very low abundance at the 
blastocyst stage, therefore gel extraction was used to obtain enough starting 
material for standard curves. End-point PCR was initially used to amplify the 
target sequence and products were run on a 1% agarose gel at low voltage for 
greater resolution. Products were visualised under UV and bands of correct size 
were cut out using a sterile scalpel blade and placed in pre-weighed tubes. Tubes 
were re-weighed and weight of gel calculated. The E.Z.N.A Gel extraction kit 
(D2500-01) was used to isolate pure DNA. The band of interest was cut from the 
gel, dissolved in binding buffer and applied to a HiBind DNA spin-column. DNA 
was then washed and eluted ready for subsequent applications. The DNA 
concentration was measured using a Nanodrop Spectrophotometer. DNA was 
measured by wavelength absorbance at 260 nm of 1 μl of sample to give a final 
concentration of ng/μl. A 260/280 ratio of 1.8 or greater was desired to confirm 
the purity of the DNA sample. The sample could then be utilised for generating 
real-time qPCR standard curves. 
2.7.5 Statistical analysis of results using standard curves 
Standard curve equations were used to formulate relative units (RU) of a given 
target gene for each sample. The crossing point (CP) was the quantitative unit 
acquired for all samples in a real-time qPCR run. To gain the relative 
concentration of any given sample, the CP was incorporated along with the 
equation generated from a target gene‟s standard curve (x & y values) into the 
following: 
RU = EXP (-(CP value – x value)/ y value) 
The resulting value was then divided by the RU from 18S to obtain the relative 
ratio of target gene to 18S for each sample. Ratios between treatments could then 
be averaged from the total number of samples, compared and graphed 
accordingly. Ratio averages obtained after all repeated trials had statistical 
students t-tests performed to determine statistical significance (P < .05).  
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2.8 Protein Quantification  
2.8.1 Fixation 
Pronase was used to remove the zona pellucida from blastocysts before being 
placed in 65°C depolymerised fixative for 30 min at 4°C. The fixed embryos were 
stored in PBS/PVA drops at 4°C until required. If embryos were processed later 
than two weeks after the first fixation, a re-fixation was essential.  
2.8.2 Embryo immunocytochemistry  
The immunocytochemistry (ICC) procedure with embryos was carried out in a 
conical 96-well plate. A mouth pipette with a 45-90° bend was necessary for 
transferring embryos between wells. Permeabilisation occurred in 0.1% Triton X-
100 in PBS/PVA for 15 min. The embryos were placed into 5% donkey serum 
block for 90 min to prevent non-specific binding of the primary antibodies. The 
embryos were subsequently exposed to a primary antibody (Table 3), or 
combination of, diluted in block solution overnight at 4°C. Negative control 
embryos remained in block solution without any antibody addition. Embryos were 
washed twice in PBS/PVA for 15 min each and incubated in their appropriate 
secondaries for 30 min at 38°C (Alexor Fluor® 488 or 568 donkey anti-mouse, -
rabbit, -goat or -rat, all Invitrogen). DNA was counterstained simultaneously with 
5 µg/ml Hoechst 33342 stain (Sigma, USA). The embryos were transferred 
through two 15 min washes in PBS/PVA and a final brief wash in H2O. 
Embryos were mounted onto slides by 1.3 µl of DAKO and 9 mm circular cover 
slips. The slides were observed under an epifluorescence microscope (Olympus 
BX50, Japan) to observe protein localization and photographed using Spot Basic 
software. Slides were stored in the dark at 4°C. 
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Table 3. ICC Primary Antibodies  
Antigen Dilution MAb/PAb Secondary Supplier & Cat. No 
NANOG 1:1000 Poly Rabbit Peprotech, 500- P236 
NANOG 1:50 Poly Rabbit Thermo Scientific, 
PA1-817 
NANOG 1: 30 Poly Rabbit Abcam, #21603 
NANOG 1:100 Poly Rabbit Abcam, #80892 
NANOG 1:100 Poly Rabbit Abcam, #47102 
NANOG 1:100 Poly Goat Abcam, #77095 
NANOG 1:520 Mono Mouse Abcam, #62734 
OCT4 1:200 Poly Mouse Santa Cruz, Sc-5279 
SOX2 1:30 Poly Goat R&D Systems, AF2018 
 
2.8.3 Cell immunocytochemistry 
Cells were previously seeded in dishes containing sterile 9 mm circular cover 
slips. Cover slips (with attached cells) were fixed in depolymerised 4% fixative 
for 30 min at 4°C, washed three times in PBS and quenched in 50 mM NH4Cl in 
PBS for 10 min. Permeabilisation occurred in 0.1% Triton X-100 in PBS for 10 
min, followed by 30 min at room temperature in block solution (5% donkey 
serum/ PBS). On parafilm, cover slips were placed atop 30 µl drops of primary 
antibody (see Table 3), diluted in block solution. Cells were left to incubate 
overnight at 4°C in large (10 cm) petri dishes with a lining of filter paper soaked 
in sterile H2O to maintain humidity. The cover slips were washed three times in 
PBS for 10 min the following day, then incubated in 30 µl drops of  
corresponding 488 or 568 Alexor Fluor® donkey anti-mouse, -rabbit, -rat or -goat 
secondary IgG antibodies (all Invitrogen) for 30 min at 38.5°C. DNA was 
counterstained simultaneously with 5 µg/ml Hoechst 33342 stain (Sigma, USA). 
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Negative controls were processed the same way, however instead of primary 
antibodies the cells were incubated in block solution overnight. Lastly, cover slips 
were washed three final times in PBS for 10 min, and once in H2O before cover 
slips were mounted on slides with 3 µl of DAKO. Cells were observed under an 
epifluorescence microscope (Olympus BX50, Japan) to observe protein 
localization and photographed using Spot Basic software. Slides were stored at 
4°C. 
2.9 Plasmid Vector Cloning 
2.9.1 Plasmid vector construct 
To obtain a cell line that over-expressed bovine NANOG for testing of antibodies 
a Tet-On® 3G system was used (Clontech Laboratories Inc, USA). The bovine 
NANOG sequence was obtained from GeneBank and synthesized into a plasmid 
vector containing a doxycycline-inducible TRE3G promoter by GENEART, 
Germany. The plasmid additionally contained an ampicillin resistance gene and 
cherry fluorescent marker. A second plasmid was required for transfections, 
which contained the Tet-On 3G transactivator protein responsible for initiating 
induced gene expression at the TRE3G promoter. The Tet-On 3G transactivator 
protein, compared with its earlier predecessors, has increased sensitivity to 
doxycycline. The pTRE3G-bovineNANOG-mcherry and pEF1α-TET3G plasmid 
maps are shown in Figure 9, A & B respectively. Plasmids were amplified via 
bacterial transformation and purified by DNA Maxi-preparation for cell 
transfections at a later date. Transfections were carried out by Andria Green.  
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Figure 9. Linear plasmid maps for A) pTRE3G-bovineNANOG-mcherry and B) 
pEF1α-TET3G. 
 
2.9.2 Bacterial transformation 
Plasmid vector dilutions (25 ng/µl) were prepared previously, along with LB broth 
and LB agar plates containing antibiotic (ampicillin). LB broth and agar plates 
were made to manufacturer‟s specifications on the container, and ampicillin was 
added at a final concentration of 100 µg/ml. The competent bacteria DH5α were 
slowly thawed on ice for 10-20 min. To every 100 µl of bacteria, 1 µl of plasmid 
vector solution was added. Bacteria/plasmid mixture were incubated at room 
temperature for 1-2 min, followed by heat shock of 1 min at 42°C, immediately 
followed by cooling on ice for 1 min. The bacteria was then diluted 1:10 in LB 
broth and incubated at 37°C for 30-60 min. Bacteria were spread evenly on LB 
agar plates and incubated overnight in a 37°C dry incubator. The vector contained 
ampicillin resistance so only colonies that took up the vector would survive. 
Colonies were selected the following day at the optimal growth period. Further 
incubation proceeded in LB broth on a shaker at approx 180 rpm in a 37°C 
incubator to aerate bacteria. The culture time in the incubator was dictated by the 
volume of bacteria required (For a DNA Maxi-preparation and larger volume 
required= overnight (~12 h)).  
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2.9.3 DNA maxi-preparation 
A Purelink
TM
 HiPure Plasmid Filter Maxi-prep Kit (K2100-74, Invitrogen) was 
used to isolate pure plasmid DNA from bacterial cultures according to the 
manufacturer‟s instructions. Bacterial cells were harvested by centrifugation 
(4,000 xg) for 10 min. All media was removed and replaced with 10 ml 
resuspension buffer with RNase A. The cells were then mixed until homogenous. 
Next, 10ml of lysis buffer was added to the mixture and incubated at room 
temperature for 5 min before addition of 10 ml of precipitation buffer. The 
precipitated lysate was transferred into a Maxi-Column and allowed to filter 
through by gravity flow. Approximately 50 ml of wash buffer was added to rinse 
the column and DNA of previous buffer residuals. This step could be repeated if 
necessary. To elute the DNA, 15 ml of elution buffer was added to the column 
and collected in a new tube. Subsequently, 10.5 ml of Isopropanol was added to 
the eluted DNA and left to incubate for 2 min at room temperature. DNA was 
precipitated out of solution by centrifugation at 15,000 xg for 30 min at 4°C. The 
supernatant was discarded and 6 ml of 70% ethanol was added. A further 30 min 
centrifugation was required before the supernatant was again removed and 
discarded. The resulting pellet was left to air-dry followed by re-suspension in 
300 µl of either TE buffer or DepC-H20. Lastly, to ensure all DNA was dissolved 
before quantification the re-suspended DNA was placed into a 37°C dry incubator 
for 10-15 min.     
2.9.4 DNA quantification  
Plasmid DNA concentrations were measured using a Nanodrop 
spectrophotometer. DNA was measured by light absorbance at 260 nm of 1 μl of 
sample to give a final concentration in ng/μl. A 260/280 ratio of 1.8–2.0 was 
desired to confirm the purity of the DNA sample. 
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2.9.5 Restriction digest 
To confirm the identity of the cloned plasmid a restriction digest was performed. 
The following was combined in a small tube for linear digestion; 0.5 µl restriction 
enzyme, 2 µl 10X buffer (of greatest compatibility with the enzyme used), 1µg 
DNA. The remainder was made up of H2O to a total volume of 20 µl. An 
additional 0.5 µl of a second restriction enzyme (substituted with H2O) was added 
for double digests as long as the same buffer could be used optimally for both 
enzymes. The restriction enzyme/s used depended on the restriction site/s present 
within the plasmid construct. Tubes were incubated in a 37°C water bath for 1 h 
before products were loaded in a 0.8-1.5% agarose gel. Molecular sizes were 
determined using a 1 kb+ ladder (10787-018, Invitrogen). 
2.10 Statistical Analyses 
Statistical analyses were carried out using Microsoft Excel®. For the analysis of 
developmental data, a two-tailed Fisher Exact test for independence in 2 x 2 tables 
was used to determine the significance of results. A two-tailed Students t-test with 
equal variance was used to determine significance for gene expression data. 
Statistical significance was accepted at P <0.05. 
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Chapter 3: Embryo Development 
Results 
3.1 Embryo development in 3i 
3.1.1 Introduction 
Blastocysts were produced following the standard operating procedure in the PC1 
embryology laboratory at Agresearch Ltd, Ruakura. Embryos were separated into 
groups of approximately 50-60 and cultured for seven consecutive days in their 
respective treatments unless otherwise stated. Grading occurred accordingly at 
day seven (D7) post-fertilisation where the morphological quality and stage of 
development was assessed. Quality was ranked on a scale from 1-3, with grade 1 
embryos being of highest quality (Criterion for quality assessment is outlined in 
Appendix 3). Blastocysts were also defined in one of four developmental 
categories shown in Table 4.  
Table 4. Blastocyst developmental categories for D7 morphological assessment 
Blastocyst category Description 
Early Blastocyst (EB) Blastocoel cavity visible, however is less than 50% 
of entire embryo 
Blastocyst (B) Blastocoel cavity is greater than 50% of entire 
embryo with a compact, dark ICM present. Zona 
pellucida is unchanged 
Expanded Blastocyst (XB) Blastocoel cavity is greater than 75% of entire 
embryo. Embryo size has increased and zona 
pellucida thinning is visible 
Hatched/ Hatching 
Blastocyst (HB) 
Same properties as expanded blastocyst, but zona 
pellucida has disappeared completely or embryo is 
currently hatching from it 
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Initial experiments using 3i looked at the effect of length of exposure on the 
development of bovine embryos. As inhibitors are diluted in DMSO, it served as a 
solvent control for all experiments. Preliminary experiments therefore compared 
embryo culture without DMSO (no DMSO/ control) and the addition of DMSO to 
culture medium (DMSO). These experiments were undertaken to justify that any 
change we would encounter with the inhibitors was not a consequence of DMSO 
supplementation. As a result, no significant difference was observed between the 
control and DMSO.  
The developmental data (n= 3 runs) is plotted in Figure 10, including the total 
number of embryos that cleaved (i.e. ≥ 2-cell). Both control and DMSO groups 
averaged an approximate 60% cleavage rate indicating that DMSO had no effect 
on initial cleavage. The graph also illustrates the total number of blastocysts 
present at day seven of quality grade 1-3 (TB1-3) and blastocysts of the total that 
represent grade 1-2 (TB1-2). The results are presented as a percentage of all 
embryos that were transferred into culture (nIVC). Although DMSO produced 
fewer TB1-3 at day seven, 26% compared to 35% of the control group, the 
difference was not significant at P < 0.05. Moreover, both groups had similar 
numbers of TB1-2 with 21.4% and 24.1% for DMSO and control, respectively. 
From these results we acknowledged that DMSO had no direct positive or 
negative effect on embryo culture, and could therefore validate its use as a solvent 
control for inhibitor experiments. 
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Figure 10. Development results of no DMSO (control) vs. DMSO. Percentage of 
embryos that cleaved and are ≥ 2-cell, total blastocysts grade 1-3 (TB1-3) and grade 
1-2 (TB1-2) from all embryos that were placed in culture (nIVC). Error bars indicate 
± SD. 
 
Table 5 summarises all embryo data recorded during no DMSO vs. DMSO 
embryo culture and subsequent grading, including exact numbers of blastocysts 
referred to in Figure 10. The TB1-3 that developed from those that cleaved (≥2-
cell) is also shown.  
 
Table 5. Embryo development:  no DMSO (control) vs. DMSO culture  
Culture 
condition 
N nIVC ≥2-cell TB1-3 TB1-2 TB1-3/ ≥2-
cell (%)   
Control 3 220 133 77 53 57.9 
DMSO 3 215 128 56 46 43.8 
N= number of independent IVF experiments; nIVC= number of embryos analysed. 
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3.1.2 3i culture 
Inhibitors (dissolved in DMSO) were introduced into culture at either day one (3i 
@ D1), day three (3i @ D3), or day five (3i @ D5) post-fertilisation. On the day 
of inhibitor culture, inhibitor solutions were added directly to culture media prior 
to making plates. DMSO (no inhibitors) was added at equal volumes to 3i and 
served as a control for the following experiments. No significant variation was 
observed between each treatment group and the DMSO control for embryos that 
cleaved, or the total number and quality of blastocysts obtained at day seven 
(Figure 11).  
 
 
Figure 11. 3i development results. Comparison of all four treatments; DMSO control, 3i 
@ D1, 3i @ D3 and 3i @ D5. Percentage of embryos ≥2-cell, total blastocysts grade 1-3 
(TB1-3) and grade 1-2 (TB1-2) from all embryos that were placed in culture (nIVC). 
Error bars indicate ± SD. 
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To observe an effect on the rate of development total blastocysts were further 
segregated into their respective stage of development categories. Figure 12 shows 
the proportion of blastocysts assessed in each developmental category (as dictated 
in Table 4). The percentage of blastocysts in each category (EB, B, and XB/HB) 
is given from the TB1-3 for each treatment (as shown in Table 6). For these 
results XB and HB‟s are classified together for all treatments, this is due to very 
low HB numbers as a consequence of the time of grading. Overall the largest 
difference was observed in both EB and B categories: 38% vs. 27% and 42% vs. 
52% for DMSO and 3i @ D5, respectively. These results would imply an increase 
in rate of development with 3i as more embryos were assessed at the B stage than 
EB. Regardless, no difference was observed within the later stage XB/HB 
category, and the number of blastocysts within each category was not statistically 
significant between all treatments and the DMSO control. 
   
 
Figure 12. Stage of development results with 3i culture. The proportion of 
blastocysts graded within each developmental category (EB, B and XB/HB) from the 
total number of blastocysts grade 1-3 (TB1-3). 
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In all 3i conditions, expanded blastocysts had developed and in a few cases the 
blastocysts had hatched from the zona pellucida. This indicated that the inhibitors 
did not interfere with trophectoderm formation or differentiation.  
Table 6 presents the embryo development data for 3i culture recorded for each 
treatment and the DMSO control. The exact numbers of TB1-3 and TB1-2, as 
well as the percentage of embryos that reached the blastocyst stage from those 
that cleaved (%TB1-3/Cleaved) are shown. The total number of blastocysts 
assessed in each developmental category is also displayed. 
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Table 6. Embryo Development: DMSO control vs. 3i @ D1/D3/D5 
Culture 
condition 
N nIVC ≥2-cell EB1-3 B1-3 XB/HB1-3 TB1-3 TB1-2 TB1-
3/Cleaved 
(%) 
 
 
DMSO 6 387 332 55 61 30 146 62 44% 
3i @ D1 6 382 334 48 69 35 152 62 46% 
3i @ D3 4 230 209 27 41 15 83 31 40% 
3i @ D5 4 263 248 32 62 25 119 56 48% 
N= number of independent IVF experiments; nIVC= number of embryos analysed. 
  
5
2
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3.2 Embryo Development in 2i 
3.2.1. Introduction 
After 3i results were analysed the number of culture treatments was reduced to 
two (DMSO control and 2i) for a more comprehensive evaluation of embryo 
culture with these inhibitors. The reduction was determined to increase sample 
size per treatment, but additionally focus on the effect of the two inhibitors 
(PD0325901 and CHIR99021) on the entire culture period. There had been 
reported evidence that the PD173074 inhibitor was dispensable for culture (Silva 
et al. 2008) therefore, we eliminated its use for the following experiments. Taking 
into consideration that there was no detrimental morphological effect observed 
with long term culture from day one in 3i, we felt this was the best treatment to 
define the effect of 2i on other molecular aspects. Inhibitors were added at D1 of 
culture for the entire culture period. Blastocysts at D7 were morphologically 
assessed as stated for previous pilot experiments in section 3.1.1.  
During the standard IVP procedure embryos are manually stripped to dislodge the 
majority of cumulus cells surrounding the zygote. Some cells remain attached, yet 
it normally has an unnoticeable effect on development and removal of cells is 
unnecessary for general IVP. When required, hyaluronidase is used to chemically 
remove all cumulus cells. The following results are divided into: 1) embryos that 
were manually stripped or „cumulus-intact‟, 2) embryos that were chemically 
stripped or „cumulus-free‟ and 3) pooled results of the two previous methods.  
3.2.2 Cumulus-intact culture in 2i 
Developmental results for cumulus-intact culture are displayed in Figure 13. 
Cleavage rates did not differ between DMSO and 2i, 56.3% and 55.6%, 
respectively. The DMSO control had slightly greater proportions of TB1-3 (29.6% 
vs. 25.6%) and TB1-2 (19.4% vs. 14.9%) compared with 2i. However, these were 
not significant at P < .05.    
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Figure 13. 2i cumulus-intact (CI) development results. Percentage of embryos that 
are ≥ 2-cell, total blastocysts grade 1-3 (TB1-3) and grade 1-2 (TB1-2) from all 
embryos that were placed in culture (nIVC). Error bars indicate ± SD. 
 
During cumulus-intact culture observations were made regarding the morphology 
and behaviour of cumulus cells at the D5 medium changeover. Cumulus cells in 
2i-supplemented medium appeared „sticky‟ or „flaky‟ and in some cases had stuck 
to the bottom of petri dishes. Several embryos were observed to remain encased in 
thick cumulus cell clumps and could not be dislodged. The occurrence of this 
morphology was only observed in the 2i treatment and across a number of 
different IVP experiments. In addition, a larger number of degenerate embryos 
were noticed in the 2i group. However, the number of degenerate embryos were 
not recorded consistently and therefore we do not have any evidence to  support 
this statement. 
The portion of blastocysts assessed in each developmental category at D7 is 
depicted in Figure 14. A minor increase in the proportion of blastocysts (B) was 
detected (44.5% vs. 40.2%) and a decrease in the number of early blastocysts (EB; 
11.4% vs. 16.8%) in 2i. The difference was statistically insignificant in both 
categories. The proportion of expanded blastocysts (XB) remained similar (41.0% 
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vs. 41.2%), as did the proportion of hatched blastocysts (HB; 2.0% vs. 3.3%). All 
comparisons between DMSO and 2i developmental categories were not 
significant at P < .05. 
 
 
Figure 14. Stage of development results with cumulus-intact (CI) culture. Bars, 
representative of each group (DMSO control and 2i), are divided into the portion of 
blastocysts graded within each developmental category (EB, B, XB and HB) from 
the total number of blastocysts grade 1-3 (TB1-3). 
 
3.2.3 Cumulus- free culture in 2i 
We hypothesised that the previous observations of cumulus cell growth could 
perhaps be a factor influencing 2i embryo development and that we may see more 
profound effects if the cumulus cells were removed. To exclude this variable we 
therefore decided to remove cumulus cells prior to culture by a brief vortex in 
hyaluronidase.  
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proportion of TB1-3 (34.0% vs. 35.6%) and TB1-2 (22.5% vs. 24.1%) are 
marginally greater in 2i compared with DMSO, which is in contrast to what was 
observed with cumulus-intact culture. However, the previous figures are not 
significant at P < 0.05.  
 
 
Figure 15. 2i cumulus-free (CF) development results. Percentage of embryos that are 
≥ 2-cell, total blastocysts grade 1-3 (TB1-3) and grade 1-2 (TB1-2) from all embryos 
that were placed in culture (nIVC). Error bars indicate ± SD. 
 
Total blastocysts grade 1-3 from cumulus-free culture were divided into their 
respective blastocyst development categories and findings displayed in Figure 16. 
The portion of HBs was significantly greater in 2i than DMSO, 4.4% vs. 1.6%  at 
P < 0.01. Whereas, no significant difference was found for any other category. It 
may be worthy to note that within the early blastocyst categories (EB and B), 
DMSO had a greater proportion of blastocysts than 2i. However on the other 
hand, 2i had a greater proportion of later stage blastocysts (XB and HB) than 
DMSO.  
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Figure 16. Stage of development results with cumulus-free (CF) culture. Bars, 
representative of each group (DMSO control and 2i), are divided into the portion of 
blastocysts graded within each developmental category (EB, B, XB and HB) from 
the total number of blastocysts grade 1-3 (TB1-3). ** = P < .01 compared with 
DMSO control. 
 
3.2.4 Pooled 2i results 
Figure 17 presents overall statistics (including both cumulus-intact and cumulus-
free results) of the total percentage of embryos that cleaved (≥ 2-cell), TB1-3 and 
TB1-2. In total, 28 independent IVF runs were completed with morphology 
assessed on 868 and 870 blastocysts for DMSO and 2i, respectively. As evident, 
TB1-3 did not differ between the two groups, neither did the TB1-2. The results 
were confirmed by significance testing. Cleavage rates did not vary between 
treatments and were also not significant at P < 0.05.  
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Figure 17. Overall development results for cumulus-intact and cumulus-free data (CI 
& CF). Percentage of embryos that are ≥ 2-cell, total blastocysts grade 1-3 (TB1-3) 
and grade 1-2 (TB1-2) from all embryos that were placed in culture (nIVC). Error 
bars indicate ± SD. 
 
Stage of development results, for all 28 runs, are displayed in Figure 18. The total 
proportion of HBs was significantly greater in 2i than DMSO, 4.1% vs. 1.7%  at P 
< 0.01. Additionally, the total proportion of EBs was significantly less in 2i than 
DMSO, 16% vs. 19.9% at P < 0.05. The major categorical groupings of B and XB 
remained insignificant with approximately 80% of all blastocysts attributed to 
either category. Together these results suggest that there is a subtle increase in the 
rate of development of embryos cultured in 2i. 
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Figure 18. Stage of development result of overall CI and CF culture. Bars, 
representative of each group (DMSO control and 2i), are divided into the portion of 
blastocysts graded within each developmental category (EB, B, XB and HB) from 
the total number of blastocysts grade 1-3 (TB1-3). * = P < .05 and ** = P < .01 
compared with DMSO control. 
 
Observations recorded during day seven grading made reference to the size of 2i 
embryos that were irrespective of stage of development. A number of blastocysts 
in 2i were much larger than their DMSO counterparts, which was most obvious 
for the expanded blastocyst category when the zona pellucida first permits the 
expansion of the developing embryo.   
Table 7 presents all developmental data collected during 2i embryo culture. This 
includes both cumulus-intact and cumulus-free results over the entire 
experimental period.  
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Table 7. Embryo development: DMSO control vs. 2i 
Culture condition N nIVC ≥ 2-cell EB1-3 B1-3 XB1-3 HB1-3 TB1-3 TB1-2 TB1-
2/TB1-3 
(%) 
TB1-
3/cleaved 
(%) 
Cumulus- 
intact 
DMSO  10 823 463 41 98 100 5 244 160 65.6 52.7 
2i  10 824 458 24 94 87 7 211 123 58.3 46.1 
Cumulus- 
free 
DMSO  18 1835 1268 132 237 245 10 
a 624 413 66.2 49.2 
2i  18 1853 1305 115 232 283 29 
b 659 446 67.7 50.0 
N= number of independent IVF experiments; nIVC= number of embryos analysed; 
ab
 rows with these different superscripts within a column differ P < 0.01.
6
0
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3.3 Blastocyst Quality Assessment: Total Cell 
Nuclei 
3.3.1 Introduction 
To further investigate the morphological differences between DMSO and 2i 
blastocysts we used differential staining to quantify cell numbers. The technique 
allowed for the number of putative ICM, TE and total nuclei in blastocysts to be 
measured. Expanded blastocysts grade 1-2 were used as these gave the most 
accurate results during differential staining and produced the greatest clarity under 
the microscope. ICM and TE cells were identified by blue (Hoechst DNA stain) 
and pink (propidium iodide) coloration, respectively, and cell numbers were 
quantified the same day using Scion Image software (Beta 4.0.2, 2000). 
Blastocysts were sourced from three individual IVF experiments and differential 
staining commenced directly following day seven grading.  
3.3.2 Differentially stained TE and ICM in bovine 
blastocysts 
The average ICM, TE and total cell nuclei (± SD) in DMSO control and 2i 
expanded blastocysts are presented in Table 8. The number of embryos analysed 
(n) was 27 and 37 for DMSO and 2i, respectively. DMSO control embryos had on 
average significantly less ICM (43 vs. 57, P < .01) and TE cell numbers (69 vs. 
89, P < 0.001). As a result, a significant increase in the average total number of 
cells was observed in 2i cultured embryos (143 vs. 110, P < 0.001). The ICM: 
Total cell ratio, was equivalent between the two treatments which indicates a 
proportional allocation in cell nuclei to ICM and TE. The increase in cell numbers 
is therefore not specific to one lineage, and represents an overall increase in cell 
nuclei of blastocysts cultured in 2i.    
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Table 8. Total nuclei numbers and allocations of nuclei (mean ± SD) to ICM and 
TE in DMSO control vs. 2i expanded blastocysts.  
 
 
 
No. of nuclei 
 Culture condition n N ICM TE  Total ICM: Total 
DMSO 3 27 43 ± 15
a 
69 ± 18
a 
112 ± 28
a 
0.39 ± .11 
2i 3 37 57 ± 24
b 
89 ± 24
c 
147 ± 46
c 
0.40 ± .12 
n= number of independent IVF experiments; N= number of embryos analysed; 
ab 
rows with these 
different superscripts within a column differ P < 0.01; 
ac 
rows with these different superscripts 
within a column differ P < 0.001. 
 
Figure 19 displays representative photographs of both DMSO control and 2i 
cultured embryos as viewed directly following the differential staining procedure. 
Photographs were taken on an epifluorescence microscope with an RGB filter at 
200x magnification (Olympus BX50, Japan). 
3.4 Embryo Development Summary  
Culture in 2i did not have any significant effects on cleavage, and the total 
number of embryos to reach the blastocyst stage. Additionally, no significant 
difference in morphological quality was observed between 2i and the DMSO 
control blastocysts at D7. Overall however, there was a significant increase in the 
proportion of hatched blastocysts at the expense of the early blastocysts in 2i 
cultured embryos. This effect was more profound with the absence of cumulus 
cells from culture. The number of cells in blastocysts cultured in 2i was found to 
be significantly greater than the DMSO control, with an increase in cells 
contributing to both TE and ICM lineages. 
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Figure 19. Differential staining of DMSO and 2i expanded blastocysts. DMSO and 2i 
embryos presented in the left and right columns, respectively. All expanded blastocysts 
were grade 1-2. Blue (Hoechst) and pink (propidium iodide) colours represent ICM and 
TE cells, respectively. Scale bar = 100 µm. 
  
 64 
 
Chapter 4: Gene Expression 
Analyses 
4.1 Introduction 
In contrast to the available information on mouse embryos, little is known of the 
markers that govern the events of pre-implantation development in cattle. This is 
partly due to the unavailability of tools and methods that specifically work in 
bovine, but also driven primarily by the species-specific differences in the 
temporal and spatial expression of the transcription factors usually associated with 
lineage specification in mice. As epiblast markers are simultaneously key 
indicators of the establishment of the pluripotent cell population, it is fundamental 
to the derivation of true ESCs in cattle to identify specific lineage markers 
(Munoz et al. 2008b).  
Our objective was to improve characterization in bovine embryos of a few of the 
core pluripotency-maintaining markers associated with mice; NANOG, OCT4, 
SOX2 and DPPA3. As we had observed a significant increase of the TE cells in 2i 
blastocysts, we were also curious to look into expression of the TE marker; 
CDX2. We initially focused on intact blastocyst samples to determine if gene 
expression was detectable and whether 2i culture had any effect on overall 
transcription. These experiments were followed by a study into mRNA expression 
of these genes within the specific lineages, ICM and TE, using bisected blastocyst 
samples (section 4.2). We initially used embryos cultured without the inhibitors to 
optimise the bisection method and also to provide us with control results once our 
method worked well. Subsequently, we aimed to assess whether these markers 
were differentially expressed in either TE or ICM. We then examined the 
expression profiles of bisected blastocysts cultured in 2i to compare the effect of 
the inhibitors. 
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4.2 Effect of 2i on Pluripotent Marker Gene 
Expression in Intact Blastocysts 
The embryos for RNA extraction were sourced from IVF experiments at D7 post-
fertilisation. Blastocysts grade 1-3 from the three treatment groups; no DMSO 
(control), DMSO (solvent control) and 2i were placed into TRIZOL® and stored 
at -80°C until required for the extraction process. Following RNA extraction and 
cDNA synthesis, the cDNA samples were amplified by RT-PCR with bovine 18S 
primers, and subsequently run on a gel. If a single DNA band was observed at 87 
bp, the sample was used for real-time quantitative PCR (qPCR) experiments. 
Samples were removed from analyses if cDNA synthesis had not been successful 
(no band).  
In all experiments gene expression was normalised to the housekeeping gene, 
18S, to produce a relative ratio for each sample presented in relative units (RU). 
Results presented in figures below are representative of the average relative ratio 
of gene expression from a number of individual IVF experiments (n) with N 
corresponding to the total number of blastocysts analysed. Blastocyst samples 
were analysed by qPCR in duplicates where possible given the very small amount 
of starting material. For all primer details refer to Table 2, section 2.6.4. 
4.2.1 Relative gene expression of pluripotent markers  
The relative expression ratio of NANOG, OCT4, SOX2, DPPA3, and CDX2 in no 
DMSO, DMSO and 2i intact blastocysts is displayed in Figure 20. NANOG 
expression was found to be significantly increased in 2i cultured blastocysts 
compared to both control groups (no DMSO and DMSO) at P < 0.01. This 
corresponded to a 2.3- and 2.7-fold increase in the abundance of NANOG 
transcripts from the no DMSO and DMSO controls, respectively. No significant 
difference was observed between the no DMSO and DMSO treated embryos for 
NANOG transcription. 
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SOX2 expression was interesting as we observed a significant difference (P < 
0.05) between the DMSO control and both the no DMSO and 2i blastocysts. 
Surprisingly, 2i maintained expression at levels equivalent to the no DMSO 
control. This result indicates that the use of DMSO has a negative effect on SOX2 
transcription, which is seemingly recovered in the presence of 2i.  
In contrast, no significant differences were detected between no DMSO, DMSO 
and 2i blastocysts for OCT4 expression. Similarly, no significant difference was 
detected in DPPA3 and CDX2 expression between no DMSO, DMSO and 2i 
treated blastocysts. 
The finding that NANOG is consistently up-regulated in 2i supports our 
hypothesis that 2i does enhance pluripotent characteristics in the bovine 
blastocyst. Based on our experimental results, the effect of 2i is limited to 
NANOG and possibly SOX2 transcription as all other genes were seemingly 
unaffected. 
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Figure 20. Relative gene expression analysis for NANOG, OCT4, SOX2, DPPA3 and 
CDX2 in no DMSO, DMSO and 2i cultured D7 embryos. Data are presented relative to 
18S mRNA abundance. Different superscripts denote differences (ab = P < 0.01, ac = P 
< 0.05) between culture conditions. Error bars indicate ± SEM. n = independent IVF 
experiments, N = total number blastocysts.  
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4.3 Lineage Specificity of Pluripotent Marker Gene 
Expression 
The next objective was to assess and quantify the expression of NANOG, OCT4, 
SOX2, DPPA3 and CDX2 in the ICM and TE lineages independently. As little 
information exists on the localisation of these genes, we aimed to measure and 
confirm whether they were differentially expressed in either the TE or ICM of 
bovine blastocysts. We initially analysed bisected blastocysts that were cultured 
without DMSO or inhibitors to optimise the bisection technique. Subsequently, 
experiments including the DMSO control and 2i treatment groups were 
performed. 
The bisection of blastocysts was carried out to obtain representative samples from 
the ICM and TE lineages. It was impossible to isolate the ICM without some 
contaminating cells from the overlying polar TE, however to avoid confusion 
these samples are still referred to as ICM. In contrast, the TE samples will 
comprise purely TE cells. Regardless, this method will still allow us to obtain the 
relative information we require as the majority of cells in the ICM/TE samples 
will belong to the ICM lineage.  
The embryos for all bisections were sourced from IVF experiments between D7 
and D8 post-fertilisation. Expanded blastocysts grade 1-2 were used as these had 
clear ICM and TE boundaries. Bisections were carried out by Bjorn Oback using a 
splitting blade mounted on a micromanipulator. Bisected pieces were placed into 
separate tubes of TRIZOL® and stored at -80°C until required for the RNA 
extraction process (the bisection method is illustrated in Figure 7, section 2.3). 
Samples were verified as previously described (section 4.2) by RT-PCR before 
being used for real-time qPCR experiments.  
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4.3.1 Pluripotent marker gene expression in untreated 
bisected blastocysts 
The results presented here are from samples obtained from untreated bovine 
blastocysts. The number of independent IVF experiments (n) = 3 (TE) and 5 
(ICM), and total number of blastocysts (N) = 25 (TE) and 64 (ICM). Two ICM 
samples were obtained by immunosurgery. These samples will not contain TE as 
the procedure involves the chemical removal of the TE cells. We chose not to 
continue with this method for subsequent experiments as all TE cells were 
sacrificed in the process, therefore we could not obtain TE and ICM samples that 
corresponded to the same blastocysts. Nonetheless, these are valuable ICM 
samples and are included in the results below.  
The relative expression ratio for NANOG, OCT4, SOX2, DPPA3 and CDX2 in TE 
and ICM from bisected blastocysts is presented in Figure 21. We found that 
NANOG and SOX2 transcripts were barely detectable in the TE and alternatively 
were enriched in the ICM. Both results were statistically significant and indicate 
that these genes are ICM-specific. The expression of DPPA3 mRNA was 
detectable in both ICM and TE, although the ICM had over a 2-fold greater 
relative expression than observed in the TE. However, DPPA3 expression in the 
ICM compared to the TE was insignificant (P < 0.053). OCT4 was likewise 
expressed in both lineages and accordingly the relative ratios of both ICM and TE 
were similar. On the other hand, CDX2 transcripts were detected at slightly 
greater abundance in the TE but these results were not significant.  
These results establish that NANOG and SOX2 are potential markers of the ICM 
in bovine blastocysts. DPPA3, to a lesser extent, also provides us with evidence to 
suggest that it could be somewhat restricted to the ICM at D7/D8. Protein 
analyses will be required to assert if these genes subsequent proteins are specific 
to the ICM.  
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Figure 21. Relative gene expression of NANOG, OCT4, SOX2, DPPA3 and CDX2 in 
bisected bovine blastocysts. Data are presented relative to 18S mRNA abundance. Error 
bars indicate ± SEM. ** = P < 0.001, * = P < 0.01.  
 
4.3.2 Effect of 2i on pluripotent marker gene expression in 
bisected blastocysts 
Bisected samples were collected as described previously from blastocysts cultured 
with DMSO and 2i. The following results illustrate the relative gene expression of 
NANOG, OCT4, SOX2, DPPA3 and CDX2 in the TE and ICM from these bisected 
blastocysts. No significant differences were observed between the untreated 
bisected blastocysts (previous results) and DMSO controls. Significance testing 
was excluded from SOX2 and CDX2 results as sample numbers were limited (n= 
1). Therefore, as further samples are required to assert differences between 
treatments we report preliminary results for these genes from experiments to date.   
The relative expression of NANOG, OCT4, SOX2, DPPA3 and CDX2 in the TE 
and ICM from DMSO and 2i bisected blastocysts is shown in Figure 22. NANOG 
transcripts are detected in greater quantity in the ICM of blastocysts in both 
DMSO and 2i, which is the same trend we observed between TE and ICM in 
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untreated blastocysts. The abundance of NANOG transcripts in the ICM of 2i 
blastocysts significantly (P < 0.05) exceeded the relative expression observed in 
the control group (DMSO), and likewise the untreated blastocysts (Figure 21). 
However, no significant difference was observed between the two groups for 
NANOG expression in the TE. These results provide further evidence that 
NANOG is an ICM-specific marker in cattle and that 2i elicits an up-regulation in 
the ICM, which is consistent with the findings we observed in intact blastocysts. 
Bisected blastocysts cultured in 2i exhibited a slight increase in OCT4 expression 
in the ICM compared to the TE. However, given that we had observed no 
difference between treatments in the intact blastocysts, this finding may be due to 
a low n. Overall, no significant difference is present between TE and ICM in 2i or 
between treatments.  
The DMSO control and 2i treatment had a very limited number of samples for 
SOX2 analyses, therefore results remain speculative. However, it is worthy to note 
that SOX2 transcripts were detected in greater abundance in the ICM of both 
treatments providing further support that SOX2 could be a potential ICM-specific 
marker. Both DMSO and 2i showed the same trend and similar values of relative 
expression. 
The relative expression of DPPA3 shows an increase in the ICM of both DMSO 
and 2i bisected blastocysts compared to their respective TE counterparts. These 
values were not significant, but also follow the same trend we observed in 
untreated bisected blastocysts.  
Unfortunately, we were only able to analyse one sample from each of the DMSO 
control and 2i for CDX2 expression in the TE and ICM. However, there was a 
noticeable difference between the TE and ICM expression with CDX2 transcripts 
detected in greater quantity in the TE in both DMSO and 2i. These results support 
the observation that CDX2 is a marker of TE in cattle, and therefore we would 
expect to observe small quantities in the ICM samples as these also contain some 
TE cells. We additionally identified no difference between the DMSO control and 
2i in relative abundance of CDX2 transcripts.  
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Figure 22. Relative gene expression analysis for NANOG in TE (blue) vs. ICM (red) of 
DMSO and 2i cultured D7/D8 bisected blastocysts. Data are presented relative to 18S 
mRNA abundance. * = P < 0.05 compared against control ICM. Error bars represents ± 
SEM. 
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4.4 RNA Analyses Summary 
In summary, we found that NANOG was significantly up-regulated in 2i and that 
this was specific to the ICM of bovine blastocysts. SOX2 was additionally found 
to be restricted to the ICM in blastocysts and was affected by DMSO, while 
blastocysts cultured in 2i restored expression to normal levels (no DMSO control). 
All other genes (OCT4, DPPA3 and CDX2) transcription levels were unaffected 
by the presence of 2i.  
Interestingly, in the bisected blastocyst samples the factor DPPA3 was also found 
to be differentially expressed and in greater abundance in the ICM than the TE. 
The trend reversed for CDX2, which was shown to be expressed in greater 
abundance in the TE. In contrast, OCT4 was the only gene we observed to be 
equally expressed in both the TE and ICM of bisected blastocysts. Ongoing 
experiments will help to further validate these observations.  
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Chapter 5: Protein Localisation 
5.1 Introduction 
In this chapter we investigate the localisation of NANOG and SOX2 proteins 
through a method known as immunocytochemistry (ICC). ICC is a common 
laboratory technique which involves using primary antibody preparations to detect 
specific cellular antigens (or proteins). A second fluorescent-labelled antibody is 
then used to bind with the primary antibody to amplify detection and signal the 
protein of interest under a microscope (Holmseth et al. 2006). This technique 
would enable us to observe where our specific proteins were located in the bovine 
blastocysts.  
Our intentions were to explore the translational profiles of bovine blastocysts with 
reference to what information we had already obtained from the mRNA 
quantification and whether culture in 2i would affect protein expression. We 
decided to limit our study to investigate the transcription factors NANOG and 
SOX2 as both were identified as being transcribed specifically in the ICM. 
Moreover, we had observed a significant increase in NANOG transcripts in 2i 
blastocysts and therefore wanted to distinguish whether this subsequently resulted 
in a correlated increase in the NANOG protein.     
5.2 NANOG Antibody Optimisation 
The NANOG protein was especially crucial to detect after mRNA results had 
shown a convincing up-regulation in 2i cultured blastocysts. However, no primary 
antibody was currently commercially available that was specific to the bovine 
NANOG antigen. A number of primary antibodies were stated to detect mouse 
and human full length antigens or specific segments within their antigens. 
Therefore, we initially compared homology of protein sequences between mouse, 
human and cattle to define our search for potential antibody candidates.  
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Table 9 shows the potential candidates that were screened, the immunogen 
recognised, and the stated reactivity in other species. Additionally, sequence 
identity (%) is an approximate calculation based on amino acid differences 
between the immunogen and bovine NANOG sequence. The Ab80892 antibody 
was ordered later after Ab21603 was permanently discontinued from the supplier. 
Consequently, this is the reason it was excluded from initial trials. 
  
Table 9. NANOG primary antibodies  
Supplier & Catalogue 
# 
Immunogen Reactivity Sequence 
identity 
(%) 
Abcam, 21603 Full-length of Ms Ms, Hu, Mk, Rat, 
Pig, Bv 
52 
Abcam, 80892 Full-length of Ms Ms, Hu, Mk 52 
Abcam, 47102 aa 1-50 of Hu Ms, Hu, Mk, Gt 68 
Abcam, 77095 aa 144-147 of Hu Hu 86 
Abcam, 62734 Full-length of Hu Hu 69 
PeproTech, 500-P236 Recombinant full-
length Hu 
Hu 69 
Thermo Scientific, 
PA1-817 
aa 135- 149 Hu Hu 100 
aa = amino acid, Hu = human, Ms = mouse, Mk = monkey, Gt = goat, Bv = bovine.  
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5.2.1 NANOG staining in murine and human ESCs 
As a positive control, all antibodies were initially tested on murine ESCs. Murine 
ESCs were cultured and fixed in 4% PFA by Andria Green. Subsequently, we 
carried out ICC on these cells. Of the six antibodies to arrive and be tested, four 
gave positive signals for the mouse Nanog protein (Figure 23 & 24). Ab47102 and 
Ab62734 were both deemed negative in relation to the negative controls. This 
result indicated that either the antibodies had been somehow compromised or that 
they did not recognise the mouse antigen as they are both directed against the 
human NANOG protein. However, Ab47102 was stated to positively cross-react 
with the mouse protein. The Peprotech and Ab77095 antibodies gave the clearest 
results. This was interesting as both were stated to specifically recognise 
sequences of the human NANOG antigen and worked better than Ab21603 which 
should have recognised the full-length mouse antigen. The DNA stain was 
accidentally excluded and therefore phase contrast photographs were taken to 
display individual nuclei instead. 
We concluded based on these results that Ab77095, Ab21603, Peprotech and 
Thermo NANOG antibodies positively detected the mouse NANOG antigen.  
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Figure 23. Positive control staining of NANOG antibodies on mESCs. Phase contrast of 
cell nuclei (left) and NANOG staining (right) for antibodies raised in rabbit. NC = 
negative control. Scale bar = 100 µm. 
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Figure 24. Positive control staining of NANOG antibodies on mESCs. Phase contrast of 
cell nuclei (left) and NANOG staining (right) from antibodies raised in goat (Ab77095) 
and mouse (Ab62734). NC = negative control. Scale bar = 100 µm. 
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 To test the two unsuccessful antibodies in mESCs staining (Ab47102 and 
Ab62734), and confirm which antibodies would detect the human NANOG 
antigen, we used human ESCs (H1, Wavell Research Institute, Wisconsin, USA). 
To ensure the human ESCs stained were undifferentiated colonies, a primary 
antibody known to stain positively in human ESCs was included as a further 
control (OCT4, Sc-5279). In human ESCs, NANOG and OCT4 have been 
reported to co-occupy many target genes and their expression is lost from 
differentiated cells (Boyer et al. 2005). 
We found of all the antibodies tested (excluding Ab80892) that the Peprotech 
NANOG antibody worked extremely well (Figure 25). The staining was 
specifically located in the nucleus of undifferentiated cells within human ESC 
colonies. All other antibodies tested failed to produce a positive result, which was 
interesting considering they all (except Ab21603) were raised against the human 
NANOG protein.  
From these results we can only conclude that the Peprotech NANOG antibody 
detected the human antigen. We can exclude the possibility that the NANOG 
protein was not present in these cells as OCT4, a marker of undifferentiated 
colonies, was used as a double stain. Additionally, the fact that the Peprotech 
NANOG and OCT4 stained positively verifies that the method and secondary 
antibodies used work well, and are therefore not a factor in the negative results. 
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Figure 25. Positive control staining of Peprotech 500-P536 NANOG and OCT4 in hESCs. H33342 DNA stain displays cell nuclei (blue) with NANOG 
(green) and OCT4 (red) staining and NANOG/OCT4 merge. NC = negative control. Scale bar = 100 µm.  
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5.2.2 NANOG staining in transiently transfected fibroblasts 
To conclusively validate that the antibodies found to work in either murine or 
human ESCs would detect bovine NANOG, bovine embryonic fibroblast cells 
were transfected with pTRE3G-bovineNANOG-mcherry and pEF1α-TET3G 
plasmids (for plasmid details refer to section 2.9.1). This would enable the testing 
of each NANOG antibody on cells that were capable of over-expressing bovine 
NANOG in the presence of doxycycline. Plasmids were transformed into DH5α 
competent bacteria and purified using a maxi-preparation kit. All techniques used 
are outlined in section 2.9. Cell culture, transfections, and ICC of the transfected 
cells were carried out by Andria Green.  
Purified plasmid DNA was identified by an analytical restriction digest. A linear 
digest of pTRE3G-bovineNANOG-mcherry was performed with Xho1 which 
resulted in a 5.6 Kb fragment. In addition, a double digest was performed using 
EcoRV and BamH1 enzymes and resulted in two fragments 4.7 Kb and 902 bp, 
respectively. The pEF1α-TET3G was linearised by the enzyme EcoR1 (7.9 Kb). 
Moreover, a double digest was performed with EcoR1 and HindΙΙΙ, which resulted 
in two fragments at 1.2 Kb and 6.7 Kb, respectively. Digested samples were run 
on a 1.5% agarose gel alongside undigested plasmid to visualise subsequent 
products (Figure 26). We observed the correct number of bands for the linear and 
double digests and accordingly the bands ran at the appropriate size for each 
plasmid. Additionally, the undigested plasmid was different to the linearised 
plasmid as you would expect to observe. The resolution of the gel (especially for 
the larger fragments) was not the greatest, however, the restriction digest 
confirmed the identity of our plasmids, and we therefore proceeded to use them 
for cell transfection.  
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Figure 26. Analytical restriction enzyme digest of pTRE3G-bovineNANOG-mcherry and 
pEF1α-TET3G. U = undigested plasmids, L = linear digestion, and D = double digest. 
 
Following cell transfections, cells were stained with all NANOG antibodies 
(excluding Ab21603 which was discontinued). We found that of all antibodies 
tested, on cells that had successfully incorporated the plasmids (red cherry 
marker), that four were positive for the detection of bovine NANOG (green, 
Figure 27). Moreover, the Ab80892, Ab47102 and Peprotech antibodies worked 
the best with the strongest stainings detected. Ab62734 antibody had a very faint 
signal, but was still positively stained. All positive stains were specific to the cell 
nucleus, distinct from the red cherry marker which was cytoplasmic. 
Unfortunately, a negative control is unavailable, but there was a clear distinction 
between cells that had no primary antibody incubation and those that were 
positive for the NANOG protein shown in Figure 27.  
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Figure 27. NANOG antibody testing on transiently transfected bovine embryonic 
fibroblasts with pTRE3G-bovineNANOG-mCherry. Cells positive for the plasmid 
express the cherry fluorescent marker (red). NANOG protein (green) detection with the 
antibodies Ab62734, Peprotech, Ab47102 and Ab80892. 
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Table 10 summarises all positive control testing with the NANOG antibodies in 
mouse ESCs (mESCs), human ESCs (hESCs) and the NANOG-transfected cells.  
 
Table 10. Summary table of NANOG antibodies and positive control detection 
Antibody Immunogen mESCs hESCs NANOG 
cells 
Ab21603 Full-length of Ms Yes N/T No 
Ab80892 Full-length of Ms N/T N/T Yes 
Ab47102 aa 1-50 of Hu No No Yes 
Ab77095 aa 144-147 of Hu Yes No No 
Ab62734 Full-length of Hu No No Yes 
Peprotech Recombinant Hu Yes Yes Yes 
Thermo aa 135-149 Hu Yes No No 
Hu = human, Ms = mouse, N/T = not tested 
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5.3 NANOG Staining in Bovine Blastocysts 
5.3.1 NANOG staining in untreated D7 blastocysts 
Subsequently, the antibodies that could be verified with either mouse or human 
positive controls and/or recognised the bovine NANOG protein were tested on D7 
bovine blastocysts. No staining above background levels could be detected for any 
of the blastocysts, regardless of the antibody used (Figure 28, 29 & 30). Figure 28 
shows the staining of antibody Ab77095 with the appropriate control as this 
antibody was raised in goat. Figure 29 presents the antibodies; Ab21603, 
Ab47102, Thermo and Peprotech, which were all raised in rabbit and therefore 
required a different negative control. Ab80892 (raised in rabbit) and Ab62734 
(raised in mouse) were processed at a later date as a double stain due to the 
limitations with blastocyst numbers at this time. Different fluorescent wavelengths 
were used to pick up each antigen and therefore the same blastocysts were able to 
be stained with both antibodies. These results are shown in Figure 30. 
 
 
Figure 28. NANOG staining of Ab77095 (raised in goat) in D7 untreated bovine 
blastocysts. NC = negative control. Scale bar = 100 µm. 
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Figure 29. NANOG staining of antibodies raised in rabbit (Ab21603, Ab47102, Thermo 
and Peprotech) in D7 untreated bovine blastocysts. NC = negative control. Scale bar = 
100 µm. 
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Figure 30. NANOG staining of Ab80892 (rabbit) and Ab62734 (mouse) in untreated D7 
blastocysts. Hoechst DNA stain (blue) and NANOG (green). NC = negative control. 
Scale bar = 100 µm. 
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Our next trials included a double stain between the NANOG antibodies 
(Peprotech and Ab80892) and a SOX2 antibody which we previously found to 
work in bovine blastocysts. We did this as a control for the method to ensure all 
reagents were fine, but also to confirm the localisation of SOX2. The SOX2 
staining was nuclear and very clearly defined in the ICM of stained blastocysts 
(Figure 31). This supports our mRNA data that SOX2 is an ICM-specific marker 
in bovine blastocysts. Unfortunately, the NANOG protein was still undetectable 
above background levels (NC), similar to previous experiments. 
 
Figure 31. SOX2 and NANOG protein localisation in D7 bovine blastocysts. Hoechst 
DNA stain (blue), and SOX2 (red) stainings were included with either Peprotech or 
Ab80892 NANOG (orange). NC = Negative control. Scale bar = 100 µm. 
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5.3.2 NANOG staining in D7 and D8 blastocysts with 2i 
Consequently we proceeded to repeat the NANOG antibodies on D7 and D8 
bovine blastocysts cultured in 2i or the DMSO control. Since we identified an 
increase in NANOG mRNA transcripts of 2i cultured blastocysts, we hypothesised 
that staining these blastocysts may improve our chances of detecting the protein. 
This time each blastocyst was double stained with a combination of two NANOG 
antibodies: Ab41702 and Peprotech. These antibodies had both detected the 
bovine NANOG in transfected cells. The idea behind the double stain was to see 
if a stronger signal could be observed as antibodies may detect different sequences 
of the same protein.  
Interestingly, we obtained a positive signal distinguishable in the TE in both 
DMSO and 2i blastocysts (Figure 32). No specific staining could be confirmed in 
the ICM of either group at D7 or D8. It is possible that these stainings are 
specifically detected in the nucleoli of the TE as seen by the spotted appearance in 
the NANOG stain that correlates with nucleus locations (Figure 33). Nonetheless, 
the stainings were very weak in both D7 and D8 blastocysts, and there was a lot of 
non-specific „noise‟ included. Regardless, the level of NANOG expression was no 
different whether blastocysts were cultured in the DMSO control or 2i.  
As we confirmed that these antibodies should recognise the bovine NANOG 
protein from previous control experiments with the transfected cells, we 
concluded that the levels of NANOG could overall be very low and therefore 
detection is poor using the immunocytochemistry method. Other methods with 
greater sensitivity may need to be utilised to determine the presence of NANOG 
in bovine blastocysts and whether 2i has any effect on protein expression levels.  
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Figure 32. NANOG protein localisation in A) D7 and B) D8 bovine blastocysts in 2i or 
DMSO control. NC = negative control. Scale bar = 100 µm. 
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Figure 33. NANOG protein localisation in D8 bovine blastocyst cultured in 2i. A) 
Hoechst DNA stain, B) Combined NANOG stain with antibodies; Ab47102 and 
Peprotech, C) Hoechst DNA stain of inset in B, and D) Merged images of DNA stain and 
NANOG nucleoli stain from inset in B. White Arrow points to a speculated nucleoli 
staining. Scale bar = 100 µm.  
 
5.4 SOX2 Staining in D8 Bovine Blastocysts with 2i 
As we had observed ICM specificity in D7 blastocysts, we investigated the later 
stage D8 embryos cultured with and without the presence of 2i. At this particular 
period in experiments we were exploring the effect of the inhibitors alone and 
therefore blastocysts from the treatment with only the inhibitor PD0325901 were 
included in SOX2 staining. As there were limited numbers of blastocysts stained 
within the DMSO control group, we were unable to infer whether there were any 
comparable differences in SOX2 expression between the treatments (Figure 34). 
However, overall (across all treatments) the D8 SOX2 stainings were interesting 
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as the localisation of the protein still resided within the ICM, but there seemed to 
be a restriction in the expression to a subset of cells. Interestingly, the blastocyst 
depicted for the treatment PD0325901 displays a ring type staining similar to that 
described in mice for the appearance of Sox2-positive extra-embryonic ectoderm 
(Avilion et al. 2003), and still a few SOX2-positive cells in the inner region of the 
ICM (white arrow, Figure 34). These would speculate that bovine SOX2 
expression is analogous to that observed in mice blastocysts. 
These results taken together with D7 SOX2 stainings indicate that SOX2 is an 
ICM-specific marker in bovine, but the restriction of expression in blastocysts 
gives us reason to suspect that it could be a more specific marker of pluripotent 
epiblast and/or extra-embryonic ectoderm.  
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Figure 34. SOX2 protein localisation in D8 bovine blastocysts cultured in DMSO, 
2i and PD0325901 treatments. White arrow indicates a cell positive within the 
„outer ring‟ of SOX2-posiitive cells. NC = Negative control. Scale bar = 100 µm. 
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5.5 Protein Localisation Summary 
Following thorough testing of NANOG antibodies we were unable to 
convincingly detect the NANOG protein in D7 and D8 bovine blastocysts. This 
was regardless of whether embryos were cultured in 2i or without the inhibitors. 
We did observe a strange nucleoli staining in the TE of most blastocysts at D7 and 
D8 however, these results are puzzling as to why this does not extend to the ICM. 
We propose that the sensitivity limit of the ICC technique is such that it might be 
incapable of detecting the NANOG protein. Nonetheless, we have now 
established antibodies that will detect the bovine NANOG protein for future work. 
These results are not able to reinforce our findings that NANOG is specific to the 
ICM and up-regulated in 2i. 
In contrast, we observed convincing SOX2 stainings that were nuclear and 
specific to the ICM in D7 blastocysts. These results support our mRNA data that 
SOX2 is an ICM-specific marker in cattle. We also obtained good staining from 
D8 blastocysts cultured with 2i, PD0325901 and DMSO controls and no 
difference could be observed between treatments. Alternatively, we hypothesise 
that the D8 blastocysts on the whole show a restriction of SOX2 expression to a 
subset of cells within the ICM, which could potentially be the foundation of 
epiblast tissue and/or the extra-embryonic ectoderm. 
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Chapter 6: Discussion 
6.1 The Effect of 3i/2i in Bovine Pre-implantation 
Embryo Development 
6.1.1 Morphological assessment of culture in 2i 
In 2008, the first completely chemically defined conditions for ESC culture were 
described (Ying et al, 2008). The authors used small molecular weight inhibitors 
(3i/2i) to block specific pathways associated with differentiation and subsequently 
maintain an undifferentiated, proliferative population of pluripotent cells. Nichols 
et al (2009) assessed the effect of these inhibitors on mouse embryos with 
convincing results showing a benefit of 2i culture for ESC derivation. Here we 
reported the findings of using these inhibitors during embryo culture in bovine, a 
species currently considered unpermissive for ESC derivation.    
Embryo development was assessed by the total number of blastocysts and the 
proportion of embryos that were of a transferable grade (grade 1 and 2). 
Additionally, the stage of blastocyst development was recorded with embryos on a 
progressive scale from early to late (or hatched) blastocysts. Overall, we found 
that culturing embryos in 3i had no significant effect on embryo development to 
blastocyst. Following exclusion of the PD173074 inhibitor, we found no 
significant difference for overall development to blastocyst in 2i culture. Aparicio 
et al (2010) found a significant increase in the portion of bovine embryos reaching 
the blastocyst stage and cultured from D1 with only the inhibitor CHIR99021 
(31% vs. 23% in the control). DMSO in this instance was also used as the solvent 
control. Our findings do not agree with the results of this study as we did not see a 
difference in 2i culture. However, we cannot exclude the possibility that the 
second inhibitor (PD0325901) in 2i could have the conflicting effect on 
development, which results in a balance between the two. Ying et al (2008) 
included the CHIR99021 inhibitor for ESC culture with the intention of relieving 
the GSK3-mediated negative regulation of biosynthetic pathways to restore 
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growth in ESCs. Apoptosis was relatively high in cells cultured with the other 
inhibitors (PDs), but the addition of CHIR99021 enhanced survival at low 
densities.  
Furthermore, in a study by Madan et al (2005) the effect of the single inhibitor 
U0126 (a predecessor of PD0325901) on bovine embryo culture was reported. 
The authors found no significant difference in the proportion of embryos that 
progressed to the blastocyst stage compared to controls. Moreover, embryos 
cultured in U0126 were observed to blastulate at the same time as controls. These 
results resemble our findings in that we observed no difference in embryo 
development, however we did observe an increase in the rate of development in 
cumulus-free cultured embryos in 2i. We are aware that U0126 is less specific 
than the PD0325901 inhibitor and therefore the effect may be less pronounced. 
Interestingly, the authors key finding was that the combined blockade of two 
MAPK pathways; p38 and ERK (with the inhibitors SB220025 and U0126, 
respectively), during bovine embryo culture resulted in the complete failure of 
embryos to reach the blastocyst stage. They postulated that inhibition of one 
pathway, found to have no effect, could potentially compensate for the other 
(Madan et al. 2005). This could be important as inhibition of ERK could cause 
downstream regulatory pathways to be blocked, but embryogenesis may still 
persist through the action of p38. These results imply that bovine embryo 
development may not rely exclusively on one pathway, and therefore the 
inhibition of ERK may be recovered to some extent by the MAPK pathway p38 in 
cattle.  
Within our results a small difference in total blastocysts was observed with and 
without the presence of cumulus cells. Cumulus cells are present within 
mammalian follicles and are vital for maturation and ovulation of the oocyte in 
vitro (Tanghe et al. 2002). In vitro, the removal of these cells prior to maturation 
in cattle is detrimental to the developmental competence of the embryo (Fukui & 
Sakuma 1980). Additionally, removal prior to fertilisation resulted in decreased 
sperm penetration and/or male pronucleus formation, however embryo culture 
without cumulus cells resulted in no significant difference in blastocyst rates 
compared to embryos grown in the presence of cumulus cells (Zhang et al. 1995).  
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Unexpectedly, in our experiments cumulus cells were abundant at the day five 
changeover in 2i and were often physically distinct to what was seen in the control 
group. Generally, cumulus cells form into a tidy ball of cells centred in the middle 
of a group of embryos. However, embryos in 2i were often completely engulfed in 
these cells, which could not be mechanically removed in some instances, and 
often embryos were stuck to one another or to the bottom of the petri dish. 
Production notes were documented indicating a greater number of degenerate 
embryos that were observed in 2i. This observation led us to speculate that 2i was 
eliciting an effect on these cumulus cells and consequently being a detriment to 
normal development. We decided to remove the cumulus cells prior to culture to: 
1) remove any bias that may be caused by the cumulus cells and 2) to see if 
removing the cumulus cells would have any effect on development between the 
two groups. We used an exploratory approach to investigate the cumulus cell 
effect in 2i, but with no success as cumulus cells grown independent of embryos 
did not show the same effect. The explanation for this observation is therefore still 
unknown.  
As mentioned previously, an increase in the rate of development was observed in 
cumulus-free cultured blastocysts as there were a significantly greater proportion 
of embryos that had hatched and significantly fewer early blastocysts in 2i. This is 
in contrast to what was observed in mouse embryos. Lu et al (2008) found a 
marked delay in development of embryos cultured in PD908059 (the less specific, 
first generation inhibitor of ERK). At the time of grading only 6.35% of embryos 
cultured in the inhibitor were at the blastocyst stage, compared with 71.12% in the 
control. In this study, embryos were cultured from the 8-cell stage in the inhibitor. 
Similarly, Nichols et al (2009) cultured embryos from the 8-cell stage in 3i/2i, yet 
no difference in developmental rate was reported. Our finding does not agree with 
either of the previous studies and indicates a difference that might exist in either 
the ERK or GSK pathway between mice and cattle.  
In all treatments expanded and hatched stage blastocysts were present at D7, 
which indicated that the inhibitors did not compromise the integrity of 
trophectoderm cells. A loss in trophectoderm function could have resulted in 
embryos that failed to progress through to blastulation. Fortunately, this was not 
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the case and in contrast we observed larger blastocysts in 2i to their counterparts 
in the DMSO control. In accordance with our morphological observations we 
identified a significant increase in the total number of cells, which was equally 
contributed to both the ICM and TE lineages. If 2i enhances pluripotent 
characteristics, especially in the ICM, a larger number of cells is certainly not a 
disadvantage. 
The increase in blastocyst cell nuclei was similarly found to increase in a study 
carried out by Aparicio et al (2010), which used the inhibitor CHIR99021 in 
bovine embryo culture. This study analysed the total number of cells in D8 
blastocysts and found that hatched blastocysts cultured in CHIR99021 had 
significantly more cell nuclei. Unfortunately, this study did not look into the 
individual lineages. Taken together with these results, we conclude that the 
increase in cell number is most likely attributed to CHIR99021 inhibition. Cell 
numbers can be influenced by either proliferation or conversely cell death by the 
process of apoptosis. Byrne et al (1999) found that the total number of cells was 
negatively correlated with the extent of apoptosis in bovine blastocysts. The 
occurrence of apoptosis was observed mainly at the blastocyst stage in 
development and predominantly in the ICM. It has been suggested that apoptosis 
at this time may function as a cellular „quality control‟ in the ICM to remove cells 
that are damaged or developmentally incompetent (Byrne et al. 1999). Perhaps a 
larger number of cells in 2i blastocysts fit the survival criteria in the ICM, and are 
therefore not destroyed. Whether the 2i blastocysts experience fewer apoptotic 
cells or an increase in cell proliferation would be an interesting investigation for 
the future. 
If there is an increase in the proliferation of cells, or alternatively a decrease in 
cell death by apoptosis in 2i this would definitely be a factor effecting 
development. The combination of mechanical force and the production of 
regulatory molecules govern the process of zona hatching (Seshagiri et al. 2009). 
Therefore, embryo size driven by a greater number of cells could also be the 
reason we observe a greater proportion of hatched blastocysts in 2i due to an 
increased hydrostatic pressure on the zona pellucida at an earlier time point.  
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The grading system is a common laboratory practise, both in research and 
commercial in vitro embryo production. An obvious limitation of this method of 
evaluation is that it is subjective and is dependent on the individual researcher‟s 
experience. It can also lead to inconsistent results should researchers individual 
perceptions on what constitutes a certain type of blastocyst be different. However, 
grading provides a non-invasive and rapid evaluation based on visual assessment, 
that in conjunction with other parameters has been shown to reliably determine an 
embryo‟s potential viability (Overstrom 1996). Given that our embryo 
development results are all graded by the same researcher we can exclude that this 
is an extraneous variable within our data set. 
6.1.2 Molecular assessment of culture in 2i 
We proceeded to measure the effect of 2i by investigating the molecular aspects of 
the pluripotent state, namely mRNA and protein expression of key transcription 
factors. We looked at four genes (NANOG, OCT4, SOX2 and DPPA3) at the core 
of the pluripotent network in mice (Nichols et al. 1998; Mitsu et al. 2003; Payer et 
al. 2003; Masui et al. 2007) and assessed their relative abundance as a ratio to 18S 
in bovine blastocysts and within the TE and ICM of bisected blastocysts.  CDX2 
as a known TE marker in mice (Strumpf et al. 2005) and bovine (Berg et al. 2011) 
was included in analyses to assess if its expression was altered by culture of 
embryos in 2i. Of the five genes, only NANOG and SOX2 were significantly 
affected by the presence of the inhibitors or DMSO supplementation. 
Interestingly, these two genes were also the only transcripts shown to be ICM-
specific in D7/D8 bisected blastocysts. If 2i enhances pluripotent characteristics 
as seen in mice, then we would expect to observe changes primarily associated 
with the establishment of the epiblast lineage within the ICM.  
6.1.2.1 NANOG 
Our mRNA analyses showed a reliable increase in NANOG transcripts, which was 
up-regulated in the ICM in 2i blastocysts. The authors of a recent study showed 
that ERK inhibition in bovine blastocysts by the FGF receptor inhibitor 
PD173074 (constituent of 3i) similarly increased NANOG expression (P < 0.05) in 
D8 blastocysts after 24 hours of culture (Yang et al. 2011). We reported a highly 
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significant (P < 0.01) increase in NANOG after culture from D1 to D7 in 2i. This 
proposes the idea that there may be a critical period for when culture with these 
inhibitors does elicit the observed increase in NANOG transcription and that the 
ERK inhibitor (PD0325901) is most likely responsible for this increase. As we 
observed no morphological detriment to culturing embryos in 3i from D1, D3 and 
D5 post-fertilisation, it may be of interest to define if the observed NANOG up-
regulation is affected by length of exposure to these inhibitors.   
The convincing increase in the abundance of NANOG transcripts has suggested 
that regulation may be somewhat conserved between species as up-regulation of 
this gene is also apparent in mouse blastocysts cultured in 2i (Nichols et al. 2009). 
The Nanog transcription factor in mice has been surmised as the main 
choreographer in the acquisition of naïve pluripotency, which is crucial for 
epiblast development and for the derivation of viable ES cells (Mitsu et al. 2003; 
Silva et al. 2009). Mitsu et al (2003) demonstrated that the deletion of Nanog 
resulted in a loss of pluripotency in both ICM and ESCs, and elevated Nanog 
expression was sufficient to maintain self-renewal of ESCs in the absence of the 
cytokine LIF. This report first demonstrated the importance of Nanog for the 
establishment of pluripotency in mice. Likewise, NANOG is considered a key 
player in the network of pluripotent regulators in human ESCs (Boyer et al. 2005), 
and is one of four factors that can reprogram human somatic cells back to a state 
of pluripotency (Yu et al. 2007), referring to the ability to obtain induced 
pluripotent stem cells or iPSCs (Takahashi & Yamanaka 2006).  
In cattle, the role of NANOG is yet to be characterised, but it is progressively 
expressed in pre-implantation blastocysts, ESC-like cells and iPSCs that exhibit 
pluripotent characteristics (Kuijk et al. 2008; Gong et al. 2010; Huang et al. 2011; 
Sumer et al. 2011). A few of these studies have speculated that NANOG 
localisation has similarities between species and that there may be functional 
preservation in mammals for this particular protein. If this is true our finding that 
NANOG is increased in the presence of 2i could be a vital piece of information 
that links ERK signalling with lineage establishment, and subsequently the 
pluripotent cell population, in cattle.   
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Embryo culture in 2i dramatically expanded the Nanog-positive compartment 
(epiblast) in the ICM of mouse blastocysts which could then be clonally expanded 
in vitro in the form of ESCs. The resulting colonies were established at high 
efficiencies (54%) in the presence of 2i and LIF from single epiblast cells 
(Nichols et al. 2009). The process of obtaining embryo-derived stem cells from 
the ICM of 2i cultured bovine blastocysts will be the next step to assessing 
whether embryo culture in 2i has ensuing benefits for establishing colonies of 
potential pluripotent cells.   
In mice, the dramatic increase in Nanog protein as a result of 2i culture was due to 
an expansion in the number of cells that were Nanog-positive (epiblast) at the 
expense of those that were Gata4-positive (hypoblast) in the ICM (Nichols et al. 
2009). As we were unable to detect the NANOG protein in bovine ICM, we could 
not investigate whether we would find analogous results to those observed in 
mice. Kuijk et al (2008) illustrated, with the NANOG antibody Ab21603, that 
several cells of the ICM in bovine blastocysts stained positively for NANOG 
while others did not. They suggested that the restriction of NANOG to a subset of 
cells in the ICM would most likely correspond to epiblast tissue. However, we 
could not detect a specific stain with the identical antibody even after repeating 
the authors‟ exact ICC method. Additionally, we have found no other literature 
that has shown the convincing detection of NANOG in bovine blastocysts using 
the ICC method. The Ab21603 antibody was discontinued and unfortunately we 
were unable to make any further conclusions using this antibody.  
We did however obtain a positive stain for NANOG that was located in TE cells. 
The staining displayed a „spotted‟ pattern within the nucleus. Shuyang et al (2006) 
described a NANOG staining in goat blastocysts that was located in the nucleus of 
ICM cells, but additionally had a very intense staining in the nucleoli of TE cells. 
The nucleolus is a sub-structure of the nucleus that is not bound by a membrane. 
Its functions are numerous, including protein sequestration, but it is mainly 
regarded as an RNA processing centre (Shaw & Brown 2012). We were unable to 
detect a positive signal in the ICM of bovine blastocysts, but our stainings in the 
TE were similar to those seen in the previous study of goat blastocysts. 
Furthermore, we had used the same antibody (Peprotech, 500-P236) to detect the 
 102 
 
 
NANOG protein. Shuyang et al (2006) believe this observation suggests that the 
NANOG protein is being inactivated and subsequently destroyed by a mechanism 
reported to occur with transcription factors isolated in the nucleoli (Song & Wu 
2005). This idea is plausible as we have observed a very low abundance of 
NANOG transcripts present in TE compared with the ICM in bovine blastocysts. 
Proteins generally persevere longer in cells than mRNA transcripts and therefore, 
what we observe may be the clearance of NANOG protein following a down-
regulation in NANOG message in the TE. Further studies would be needed to 
validate this idea. However, the reason we do not detect NANOG protein in ICM 
cells is still unclear.   
6.1.2.2 SOX2  
In addition to the change in NANOG expression, we also found a significant 
down-regulation of SOX2 mRNA in the presence of the inhibitor solvent; DMSO. 
Intriguingly, SOX2 levels were restored in the presence of 2i to values equivalent 
to the untreated control. This suggests that 2i may have a positive effect on SOX2 
expression, which counteracts the negative effect seen with DMSO. DMSO is a 
common organic solvent with acknowledged embryo-toxic effects. It is known to 
variably alter gene expression and have a differentiation-inducing effect on ESCs 
(Adler et al. 2006). This is an important reason why we included the solvent 
control in our experiments to ensure we were aware of any alteration DMSO 
would cause. We were also able to show that the abundance of SOX2 transcripts 
was significantly greater in the ICM as opposed to the TE in D7/D8 blastocysts. 
Therefore, we can conclude that the changes in gene expression as a result of 
DMSO and 2i culture occur predominately in the ICM of bovine blastocysts. To 
our knowledge, the effect of 2i on SOX2 expression has not been reported for any 
other species, including mouse. 
In addition to mRNA analyses, we were able to detect the localisation of the 
SOX2 protein in D7 and D8 bovine blastocysts using ICC. We did not observe 
any differences at D8 in protein abundance between 2i, PD0325901 and control 
blastocysts, yet as a limited number of blastocysts were stained in the control 
group we hold our conclusions until further repeats are undertaken. The stainings 
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on the whole showed SOX2 was conclusively expressed in the ICM of D7 
embryos, which is complementary to our finding that mRNA transcripts were also 
detected primarily in the ICM. To our knowledge, these illustrations are the first 
to be published that show the SOX2 protein is specifically restricted to the ICM in 
D7 bovine blastocysts. Moreover, at D8 we observed a specific stain in the ICM, 
comparable with staining at D7, but the number of cells positive for SOX2 had 
reduced. The observed confinement of cells may reflect changes occurring in the 
ICM at this time. These findings would be consistent with studies that report the 
emergence of GATA4-producing primitive endoderm (or hypoblast) between days 
8-10 in cattle (Yang et al. 2011). Additionally, Vejlsted et al (2005) had identified 
the existence of two cell populations in day 12 bovine epiblast, which suggested a 
certain level of differentiation had already occurred prior to this stage in 
development.  
Sox2 is a known gene associated with pluripotency, and thus the epiblast lineage, 
in mice (Avilion et al. 2003) and humans (Boyer et al. 2005; Takahashi et al. 
2007). However, Avilion et al (2003) stated that Sox2 remained highly expressed 
in extra-embryonic ectoderm, in a ring of cells adjacent to the epiblast, in mice 
blastocysts. Therefore, Sox2 has a secondary function associated with extra-
embryonic progenitors, as well as the epiblast. Therefore, our D8 stainings were 
interesting in that if Sox2 function is conserved between species than the 
restriction of expression may represent both the epiblast and extra-embryonic 
ectoderm lineages. One particular blastocyst added support to this hypothesis as a 
very obvious ring of cells appeared to line the outer surfaces of the ICM. A closer 
look using a confocal microscope may provide answers to the localisation of these 
cells within the ICM. Regardless of SOX2s status as a core transcription factor 
associated with pluripotency, little attention has been paid to its role in other 
species. Here we show that SOX2 is specifically expressed in the ICM at D7 and 
that around D8 its expression becomes restricted to a subset of cells in the ICM. 
The exact identification of this cell population requires further investigation.  
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6.1.2.3 Other transcription factors 
In mice, the transcription factor Oct4 has been found to be exclusively expressed 
in the ICM (Palmieri et al. 1994). In contrast, the distribution of OCT4 has been 
documented to occur in the TE and ICM of bovine blastocysts (Kirchhof et al. 
2000; Kuijk et al. 2008). Similarly, goat blastocysts express OCT4 in both 
lineages, which together with the bovine expression profile, suggests a difference 
in OCT4 regulation in ruminants compared with mice. It has been proposed that 
this could be related to the longer period before implantation and the requirement 
for OCT4 to maintain TE proliferation in these species (Shuyang et al. 2006). Our 
mRNA data is consistent with these observations. In mouse blastocysts, the 
number of Oct4-positive cells increased as the epiblast domain expanded in 2i. 
Additionally, the protein was also maintained in the hypoblast which is 
characteristic of embryos in diapause, the stage of arrested development from 
which ESCs are readily derived (Nichols et al. 2009). We did not see any 
difference in the expression of OCT4 in bovine blastocysts that would suggest a 
change in transcription level of this gene. This does not exclude the possibility 
that there are more cells expressing OCT4 as we only measured OCT4 relative to 
18S. The next step would be to investigate the OCT4 protein in bovine blastocysts 
cultured in 2i. 
There is currently insufficient information available on DPPA3 expression in 
bovine pre-implantation embryos, therefore highlighting the requirement for 
further studies. We have shown that DPPA3 was found to be expressed to a 
greater extent in the ICM of bovine blastocysts. However, this observation was 
not significant, but may indicate that this factor becomes gradually restricted to 
the ICM later in development. No significant difference in DPPA3 expression was 
observed between blastocysts cultured with and without the presence of 2i.  
As we were curious regarding the significant increase in TE cells, we decided to 
investigate the expression levels of CDX2, a lineage-specific marker for TE in 
mouse blastocysts (Strumpf et al. 2005). Kuijk et al (2008) reported CDX2 protein 
to be localised within the TE of bovine blastocysts. Additionally, CDX2 
transcripts have been shown to be enriched in the TE relative to the ICM by 2-fold 
 105 
 
 
between D7-11 post-fertilisation (Berg et al. 2011). Our mRNA results did not 
show the same enrichment in the TE at D7/D8, but we did observe the same trend 
in untreated, DMSO and 2i cultured embryos. We acknowledge that our ICM 
samples do also contain some TE cells, and that this may interfere with the 
accuracy of the comparison for this particular TE-associated gene.   
The relative analysis of real-time qPCR results has its limitation in that we were 
unable to quantify absolute abundance of gene transcripts. However, as our main 
aim was to assess the differences between the 2i treatment and controls, it served 
as a good tool for our comparative studies. The blastocysts in our experiments 
averaged between 100-150 cells (dependent on treatment) and therefore, samples 
of 15 blastocysts, for example, would only contain the RNA from between 1500-
2250 cells. Large numbers of blastocysts were not always possible to obtain. This 
meant that the total cDNA generated from our starting material was low, which 
was reflected by the higher number of cycles required for the Lightcycler® to 
detect the amplified DNA product (CP).  Unfortunately the higher the CP , the 
greater the variability in results. We were unable to efficiently increase the 
starting material without compromising the quality of embryos produced by IVP 
and encountering logistic issues. However, we tried to reduce this variability by 
repeating each sample a number of times and increasing the overall number of 
individual samples per treatment.  
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6.2 Future Work 
The overall objective of the work carried out in this thesis was to assess if 2i 
enhances pluripotent characteristics in bovine blastocysts, for the purpose to 
improve derivation of embryo-derived stem cells in cattle. Therefore, future work 
would include the functional testing of whether cells from the ICM of bovine 
blastocysts cultured in 2i would establish and maintain colonies at greater 
efficiencies than untreated blastocysts.  
Aside from the functional aspect, there are some findings which could be 
investigated further. It would be interesting to explore the mechanism behind why 
we observe an increase in cells with 2i. Is this due to fewer apoptotic cells or a 
greater proliferative effect of 2i? Fouladi-Nashta et al (2005) describes a unique 
method which incorporates a TUNEL labelling assay with a differential stain. 
This enabled the detection of apoptotic cells (TUNEL) and the concurrent 
visualisation of ICM and TE cells (differential stain). This method of detection 
may be especially applicable for us to assess the level of apoptosis, whilst still 
gaining valuable information on where the apoptosis is occurring, and 
subsequently the number of cells in both lineages in our control and 2i-treated 
embryos.  
Additionally, experiments testing the use of individual inhibitors (CHIR99021 and 
PD0325901) as treatments during embryo culture would enable us to delineate 
which inhibitor is responsible for some of our key findings e.g. the increase in cell 
numbers in blastocysts, and NANOG and SOX2 up-regulation. It would also be 
important to expand our gene expression analyses to other genes essential in early 
pre-implantation development. A gene of particular interest would be the 
hypoblast marker GATA4. This gene has already been implicated to be negatively 
effected by the inhibitor PD173074 in bovine blastocysts (Yang et al. 2011). It 
would also be an interesting combination to assess the protein localisation of both 
GATA4 and SOX2 simultaneously, as these are two proteins found to be 
specifically detected in the ICM of bovine blastocysts. This would help confirm 
when lineage segregation, and importantly the pluripotent population of cells, is 
established in cattle.   
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6.3 Conclusions 
In conclusion, we have shown that bovine blastocysts cultured in 2i show 
accelerated blastocyst development. These blastocysts have more cell nuclei, 
which is attributed to a significant increase in both ICM and TE lineages 
compared with that of control embryos. The pluripotency transcription factor 
NANOG was significantly up-regulated in 2i blastocysts, which was due to an 
increase in transcription in the ICM. Another ICM-specific marker SOX2 was 
negatively affected by DMSO and restored to normal levels in the presence of 2i. 
All other lineage-specific or pluripotency-related genes tested were unaffected. 
Table 11 summarises our observations of bovine embryo culture in 2i compared 
with observations in mice detailed by Nichols et al (2009). Overall, we conclude 
that bovine blastocysts differ from mouse in their response to 2i signal inhibition 
and molecular control of pluripotency. 
  
Table 11. Embryo culture in 2i: Murine vs. Bovine observations 
Murine Observations Bovine Observations 
Delayed development Accelerated development 
Reduced TE cell number Increased TE and ICM cell numbers 
Increased Nanog-positive cells in the 
ICM 
Increased NANOG transcription. Protein 
undetectable 
Oct4 expression maintained in entire 
ICM (epiblast/hypoblast).  
OCT4 expression not affected and 
detected in both ICM and TE 
Sox2 expression not analysed Increased SOX2 transcription. ICM-
specific protein. 
TE= Trophectoderm, ICM= Inner cell mass. 
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Appendix 1: Reagents, Solutions and Media Composition 
All chemicals, unless otherwise stated, are sourced from Sigma-Aldrich, New 
Zealand Ltd. 
 
TCM 199 (Base Medium) 
Tissue Culture Medium 199 containing Earle‟s salts and L-glutamine is supplied 
by Life Technologies (# 31100-035). 
 
H199 Media 
Hepes-buffered TCM 199 contains: TCM 199 with 250 mM Stock H 
(Combination of Hepes-free acid, and Hepes Sodium Salt). 
 
B199 Media 
Bicarbonate-buffered TCM 199 contains: 0.2 mM C3H3O3Na, and 250 mM 
NaHCO3 with antibiotic: 50 mg/ml C18H36N4O11H2SO4 from Streptomyces 
(K1377).  
 
Aspiration Media 
Aspiration media contains: H199 medium + 925 IU/ml Heparin (#016128, CP 
Pharmaceuticals Ltd., UK) + 2% (w/v) foetal calf serum (FCS; Life 
Technologies).   
 
IVM Media 
IVM medium contains: B199 medium + 10% FCS (Life Technologies) with 10 
μg/ml ovine follicle-stimulating hormone (FSH; ICP), 1 μg/ml ovine luteinising 
hormone (LH; ICP), 1 μg/ml β-estradiol in absolute ethanol and 0.1 mM 
cysteamine (2-Mercaptoethylamine) added prior to use.  
 
IVF Media 
IVF medium contains: 107.7 mM NaCl, 7.15 mM KCl, 0.3 mM KH2PO4, 25 mM 
NAHCO3, 0.33 mM C3H3O3Na, 3.32 mM C3H5O3Na, 1.71 mM CaCl2:2H2O, 8 
mg/ml fatty-acid free bovine serum albumin (BSA; MP Biologicals, Auckland, 
NZ), with 0.04 mM C18H36N4O11H2SO4, and supplemented with 0.1 mM 
pyruvate, 10 mg/ml heparin, 0.2 mM penicillamine and 0.1 mM hypotaurine.  
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HSOF 
Hepes-buffered synthetic oviduct fluid (HSOF) contains: 107.7 mM NaCl, 7.15 
mM KCl, 0.3 mM KH2PO4, 5 mM NaHCO3, 3.32 mM C3H5O3Na, 0.04 mM 
C18H36N4O11H2SO4, 20 mM Hepes, 0.33 mM C3H3O3Na, 1.71 mM CaCl2:2H2O, 3 
mg/ml fatty-acid free BSA (MP Biologicals, Auckland, NZ). 
 
90% Percoll Plus 
4.5 ml Percoll Plus (GE Healthcare), 0.525 ml 10x SPTL, 0.05 ml 100x SPAD, 
0.05 ml Stock B (250 mM NaHCO3). 
 
45% Percoll Plus 
2 ml 90% Percoll Plus diluted with 2 ml 1x SPTL 
 
Hyaluronidase 
Hyaluronidase (Sigma H3506) dissolved at 0.1% concentration in H199 -BSA. 
 
ESOF 
Early Synthetic Oviduct Fluid medium contains: 107.7 mM NaCl, 7.15 mM KCl, 
0.30 mM KH2PO4, 25 mM NaHCO3, 0.33mM C3H3O3Na, 1.71 mM CaCl2:2H20, 
0.15 mM C6H12O6, 3.32 mM C3H5O3Na, 0.04 mM C18H36N4O11H2SO4, and 0.081 
g/L Non Essential Amino Acid, 1 mM Gluta-Max, and 8 mg/ml BSA.  
 
LSOF 
Late Synthetic Oviduct Fluid medium contains: 107.7 mM NaCl, 3.99 mM KCl, 
1.20 mM KH2PO4, 25 mM NaHCO3, 0.33 mM C3H3O3Na, 1.71 mM CaCl2:2H20, 
0.49 mM MgCl2:6H2O, 3.32 mM C3H5O3Na, 0.04 mM C18H36N4O11H2SO4, 1.5 
mM C6H12O6, 1 mM DNP (2-, 4-dinitrophenol) and 0.081 g/L Non Essential 
Amino Acid, 1 mM Gluta-Max, 0.22 g/L BM Essential Amino Acid and 8 mg/ml 
BSA.  
 
Pronase  
Protease from Strep.Griseus (Sigma P8811) diluted 0.5% in HSOF -Ca, -BSA 
(Osmolarity~ 305). Add 0.1 mg/ml CaCl2:2H2O, 0.1 mg/ml MgCl2:6H2O and 1 
mg/ml PVA. 
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Hoechst DNA stain 
Bis-Benzimide (H33342; Sigma B2261) in 1 mg/ml MQ-H2O. Stored at 4°C and 
used at working solution of 5 µl/ml.  
 
THSOF 
Transfer HSOF medium contains: 107.7 mM NaCl, 3.99 mM KCl, 1.20 mM 
KH2PO4, 5 mM NaHCO3, 0.33 mM C3H3O3Na, 1.71 mM CaCl2:2H20, 0.49 mM 
MgCl2:6H2O, 3.32 mM C3H5O3Na, 0.04 mM C18H36N4O11H2SO4, 1.5 mM 
C6H12O6, 20 mM Hepes, 0.081 g/L Non Essential Amino Acid, 1 mM Gluta-Max, 
0.22 g/L BM Essential Amino Acid and 8 mg/ml BSA.  
 
Fixative 
Depolymerised 4% (w/v) paraformaldehyde (PFA), 4% (w/v) sucrose, 1 M NaOH 
in PBS with a few drops phenol red indicator. 
 
TAE buffer  
2 M Tris, 250 mM Glacial acetic acid, 50 mM EDTA + 1 L H2O. 
 
PBS  
Phosphate buffered saline contains: 1.9 mM sodium dihydrogen orthophosphate 
1-hydrate, 8.4 mM disodium hydrogen orthophosphate 2-hydrate, and 150 mM 
sodium chloride in MQ-H2O. 
 
DEPC-H2O 
0.1% (v/v) diethyl procarbonate in MQ-H2O. Mixed overnight, then autoclaved 
for 30 min at 121°C. 
 
 
 
 120 
 
 
Appendix 2: Production Sheet 
 121 
 
 
Appendix 3: Criteria for D7 Grading of Bovine 
Blastocysts 
All images in Appendix 3 were obtained from the “Manual of the International Embryo 
Transfer Society” (3rd edition). Edited by David A. Stringfellow and Sarah M. Seidel. 
Published April 1988 by the International Embryo Transfer Society, 1111 North Dunlap 
Ave, Savoy, IL, USA. 
Using Agresearch terms, stage code in the following pictures is equivalent to; 4= Tight 
Morula, 5= Early blastocyst, 6= Blastocyst, 7= expanded blastocyst and 8= hatched 
blastocyst. The cycle day is the corresponding day at which the stage code would appear 
post-fertilisation. See associated comments for more information on quality code or grade 
(1-3) of pictures below.  
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Comments: 
d) Single or small blastomeres comprise less than 15% of the total cellular material and 
the embryo is consistent with the expected stage of development.  
e) Sperm on zona pellucida.  
f) Embryos with many extruded cells or debris must be carefully rolled over to determine 
the presence and quality of any viable embryo mass. 
g) Quality code 3 embryos have an embryo mass that is less than 50% of all cellular 
material within the zona pellucida. 
h) This embryo has a nice but very small mass. If the embryo mass is less than 25% of all 
cellular material, it should be given a code 4 (non-viable). 
i) Irregular shape is a common variation in blastocoel development. 
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j) Collapsing of the blastocoel is considered a normal physiological process that does not 
lower the quality grade. 
k) Extruded cells in stage code 6, 7, and 8 embryos are often pressed against the zona 
pellucida and not obvious unless the embryo has collapsed due to normal physiological 
processes or when cryoprotective additive is introduced. 
l) This embryo has a flat (even concave) surface of the zona pellucida that can cause the 
embryo to stick to the petri dish or straw. This defect alone keeps the embryo from being 
classified as quality grade 1 and should not be utilised in international commerce unless 
agreements allow for other than quality code 1 embryos. 
m) Cellular debris on the surface of the zona pellucida shows that this embryo has not 
been washed by proper procedures. 
n) This embryo has a cracked zona pellucida at the top of the picture. Embryos that do not 
have an intact zona pellucida should not be utilised in international commerce
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